Description
Title of Invention: PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR
PROPHYLAXIS OF CANCER
Technical Field
[0001]
The present invention relates to novel use of an antibody against CAPRIN-1 or a
fragment thereof in a drug such as a therapeutic and/or preventive agent for cancer.
Background Art
[0002]
Cancer is the leading cause of death. This disease is currently treated principally by
surgical therapy, in combination with radiation therapy and/or chemotherapy. In spite of
recent development of novel surgical techniques or discovery of novel anticancer agents, the
existing treatment of cancer has an insufficiently improved outcome, except for some cancer
types. With recent advances of molecular biology or cancer immunology, antibodies that
specifically react with cancer, cancer antigens that are recognized by cytotoxic T cells, genes
encoding such cancer antigens, and the like have been identified, raising expectations on
specific cancer therapy targeting the cancer antigens (Non Patent Literature 1).
[0003]
For reducing the adverse reaction of cancer therapy, it is desired that peptides,
polypeptides, or proteins recognized as antigens of the cancer should rarely exist in normal
cells and specifically exist in cancer cells. In 1991, Boon et al. (Ludwig Institute for Cancer
Research, Belgium) isolated a human melanoma antigen MAGE1 recognized by CD8-positive
T cells by a cDNA expression cloning method using autologous cancer cell lines and cancer-
reactive T cells (Non Patent Literature 2). Then, a SEREX (serological identification of
antigens by recombinant expression cloning) method has been reported, which adopts a gene

expression cloning approach to identify tumor antigens recognized by antibodies produced in
response to autologous cancer in vivo in a cancer patient (Non Patent Literature 3 and Patent
Literature 1). According to this method, some cancer antigens that are rarely expressed in
normal cells and are specifically expressed in cancer have been isolated (Non Patent
Literatures 4 to 9). In addition, cell therapy using immunocytes that specifically react with
cancer antigens or cancer-specific immunotherapy using vaccines or the like comprising
cancer antigens is under clinical trial targeting some of the isolated cancer antigens.
[0004]
In recent years, various antibody drugs for cancer treatment targeting antigenic proteins
on cancer cells have emerged in the world. These drugs have received attention because of
their certain efficacy as cancer-specific therapeutic agents. A large majority of antigenic
proteins targeted by the drugs, however, are also expressed in normal cells. As a result of
administering the antibodies, cancer cells as well as normal cells expressing the antigens are
damaged, disadvantageously resulting in adverse reaction. Thus, if cancer antigens
specifically expressed on the surface of cancer cells can be identified and antibodies targeting
the antigens can be used as drugs, these antibody drugs can be expected to achieve treatment
with less adverse reaction.
[0005]
Cytoplasmic- and proliferation-associated protein 1 (CAPRTN-1) has been known as an
intracellular protein that is expressed upon activation or cell division of resting normal cells
and forms cytoplasmic stress granules with RNAs in cells to participate in the regulation of
transport and translation of mRNAs. This protein has been found to be specifically expressed
on the surface of cancer cells and is therefore under study as a target of antibody drugs for
cancer treatment (Patent Literature 2).
Citation List
Patent Literature
[0006]

Patent Literature 1: U.S. Patent No. 5698396
Patent Literature 2: WO2010/016526
Non Patent Literature
[0007]
Non Patent Literature 1: Tsuyoshi Akiyoshi, "Japanese Journal of Cancer and Chemotherapy",
1997, Vol. 24, p. 55-519 (Japanese Journal of Cancer and Chemotherapy Publishers Inc.,
Japan)
Non Patent Literature 2: Bruggen P. et al., Science, 254: 1643-1647 (1991)
Non Patent Literature 3: Proc. Natl. Acad. Sci. USA, 92: 11810-11813 (1995)
Non Patent Literature 4: Int. J. Cancer, 72: 965-971 (1997)
Non Patent Literature 5: Cancer Res., 58: 1034-1041 (1998)
Non Patent Literature 6: Int. J. Cancer, 29: 652-658 (1998)
Non Patent Literature 7: Int. J. Oncol., 14: 703-708 (1999)
Non Patent Literature 8: Cancer Res., 56: 4766-4772 (1996)
Non Patent Literature 9: Hum. Mol. Gene 6: 33-39, 1997
Summary of Invention
Technical Problem
[0008]
An object of the present invention is to produce an antibody which targets CAPRIN-1
specifically expressed on the surface of cancer cells and has better antitumor activity than
conventional antibodies, and provide use of the antibody as a therapeutic and/or preventive
agent for cancer.
Solution to Problem
[0009]
The present invention has the following aspects:
[0010]

The present invention provides an antibody or a fragment thereof which has
immunological reactivity with a partial CAPRIN-1 polypeptide having the amino acid
sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence
identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or
prevention of cancer, comprising the same as an active ingredient.
[0011]
In one embodiment of the present invention, the cancer is breast cancer, kidney cancer,
pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix
cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia,
lymphoma, fibrosarcoma, mastocytoma, or melanoma.
[0012]
In another embodiment, the antibody is a monoclonal antibody or a polyclonal antibody.
[0013]
In an alternative embodiment, the antibody is a human antibody, a humanized antibody,
a chimeric antibody, a single-chain antibody, or a multispecific antibody (e.g. bispecific
antibody).
[0014]
The present specification includes the contents disclosed in Japanese Patent
Application No. 2011-171300 to which the present application claims priority.
Advantageous Effects of Invention
[0015]
The antibody against CAPRIN-1 according to the present invention damages cancer
cells. Thus, the antibody against CAPRIN-1 is useful in the treatment and/or prevention of
cancer.
Description of Embodiments
[0016]

The antibody according to the present invention is an antibody that recognizes and
binds to a predetermined partial polypeptide of CAPRIN-1 and has antitumor activity. The
antibody according to the present invention is more specifically an antibody that recognizes
(i.e., has immunological reactivity with) a partial polypeptide of a CAPRIN-1 protein (partial
CAPRIN-1 polypeptide) consisting of the amino acid sequence shown by SEQ ID NO: 5 or an
amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or
higher, further preferably 95% or higher sequence identity to the amino acid sequence. The
present invention has revealed that this antibody exhibits antitumor activity. The present
invention relates to all antibodies that bind to the fragments of CAPRIN-1 proteins as
described above and exhibit antitumor activity.
[0017]
The antibody against CAPRIN-1 according to the present invention may be any type of
antibody that can exert antitumor activity and includes, for example, recombinant antibodies,
for example, synthetic antibodies, multispecific antibodies (e.g., bispecific antibodies),
humanized antibodies, chimeric antibodies, and single-chain antibodies (scFv), human
antibodies, and their antibody fragments, for example, Fab, F(ab')2, and Fv. These antibodies
and fragments thereof can be prepared by methods known to those skilled in the art.
Desirably, the antibody according to the present invention has immunological reactivity with a
CAPRIN-1 protein or a partial polypeptide thereof, i.e., binds to the CAPRIN-1 protein
through antigen-antibody reaction, preferably, specifically binds to the CAPRIN-1 protein.
In this context, the phrase "specifically binding to the CAPRIN-1 protein" means that the
antibody specifically binds to the CAPRIN-1 protein without substantially binding to other
proteins. The antibody according to the present invention is preferably a monoclonal
antibody. Alternatively, the antibody according to the present invention may be a polyclonal
antibody as long as homogeneous antibodies can be stably produced. In the case of a human
subject, a human antibody or a humanized antibody is desirable for avoiding or suppressing
rejection.
[0018]

The antibody against CAPRIN-1 polypeptide according to the present invention can be
examined for its antitumor activity, as described later, by examining in vivo the inhibition of
tumor growth in a cancer-bearing animal or by examining ex vivo the presence or absence of
immunocyte- or complement-mediated cytotoxic activity exhibited by the antibody against
tumor cells expressing the polypeptide.
[0019]
The subject to receive the treatment and/or prevention of cancer according to the
present invention is a mammal such as a human, a pet animal, livestock, or a sport animal,
preferably a human.
[0020]
Hereinafter, the present invention will be described in more detail.
[0021]

Proteins or fragments thereof used as sensitizing antigens for obtaining the antibody
against CAPRIN-1 according to the present invention are not limited by animal species
serving as their origins, including humans, dogs, cattle, horses, mice, rats, and chickens. The
proteins or the fragments thereof, however, are preferably selected in view of compatibility
with parent cells for use in cell fusion. In general, mammal-derived proteins are preferred.
Particularly, human-derived proteins are preferred. For example, when CAPRIN-1 is human
CAPRIN-1, human CAPRIN-1 proteins, partial peptides thereof, or cells expressing human
CAPRIN-1 can be used.
[0022]
The nucleotide sequences and amino acid sequences of human CAPRIN-1 and
homologs thereof are available, for example, by accessing GenBank (NCBI, USA) and using
BLAST or FASTA algorithm (Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90: 5873-
5877, 1993; and Altschul et al., Nucleic Acids Res. 25: 3389-3402, 1997).
[0023]

In the present invention, with reference to the nucleotide sequence (SEQ ID NO: 1 or
3) or amino acid sequence (SEQ ID NO: 2 or 4) of human CAPRIN-1, the target CAPRIN-1 is
nucleic acids or proteins consisting of sequences having 70% to 100%, preferably 80% to
100%, more preferably 90% to 100%, further preferably 95% to 100%, for example, 97% to
100%, 98% to 100%, 99% to 100%, or 99.5% to 100% sequence identity to the nucleotide
sequence or amino acid sequence of the ORF or mature portion of the reference sequence. In
this context, the term "% sequence identity" means a percentage (%) of the number of identical
amino acids (or nucleotide bases) to the total number of amino acids (or nucleotide bases)
when two sequences are aligned such that the maximum degree of similarity (or identity) can
be achieved with or without introduced gaps.
[0024]
As the fragments of each CAPRIN-1 protein, those comprising an epitope (or an
antigenic determinant), which is the smallest unit recognized by an antibody, and having
lengths ranging from the amino acid length of the epitope to less than the full-length of the
protein can be used. The epitope refers to a polypeptide fragment having antigenicity or
immunogenicity in mammals, preferably humans. Its smallest unit consists of approximately
7 to 12 amino acids, for example, 8 to 11 amino acids. The fragments of CAPRIN-1 protein
to be used in the preparation of the antibody according to the present invention are preferably
fragments each comprising the amino acid sequence shown by SEQ ID NO: 5 or an amino
acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher,
further preferably 95% or higher sequence identity to the amino acid sequence, recognized by
the antibody of the present invention, or comprising at least an epitope consisting of
approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids,
in any of these amino acid sequences.
[0025]
Polypeptide fragments comprising the above human CAPRIN-1 proteins and partial
peptides thereof can be synthesized according to chemical synthesis methods, for example,
Fmoc (fluorenylmethyloxycarbonyl) and tBoc (t-butyloxycarbonyl) methods (Seikagaku

Jikken Koza (Biochemical Experimentation Course in English) 1, the Japanese Biochemical
Society ed., Protein Chemistry IV, Chemical Modification and Peptide Synthesis, Tokyo
Kagaku Dojin Co., Ltd. (Japan), 1981). Also, these polypeptides can be synthesized by
conventional methods using various commercially available peptide synthesizers.
[0026]
Alternatively, polynucleotides encoding the polypeptides may be prepared using
genetic engineering approaches known in the art (Sambrook et al., Molecular Cloning, the 2nd
edition, Current Protocols in Molecular Biology (1989), Cold Spring Harbor Laboratory Press;
Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A compendium of
Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons; etc.) and
incorporated into expression vectors, which are then introduced into host cells to produce the
polypeptides in the host cells. In this way, the human CAPRIN-1 proteins or polypeptide
fragments thereof of interest can be obtained.
[0027]
The polynucleotides encoding the polypeptides can be readily prepared by genetic
engineering approaches known in the art or conventional methods using commercially
available nucleic acid synthesizers. For example, a DNA comprising the nucleotide sequence
of human CAPRTN-1 gene can be prepared by PCR using a human chromosomal DNA or
cDNA library as a template and a pair of primers designed so as to be capable of amplifying
the nucleotide sequence. Reaction conditions for this PCR can be appropriately determined.
Examples of the conditions can include, but not limited to, 30 cycles each involving reaction
steps consisting of 94°C for 30 seconds (denaturation), 55°C for 30 seconds to 1 minute
(annealing), and 72°C for 2 minutes (elongation) using thermostable DNA polymerase (e.g.,
Taq polymerase, Pfu polymerase or the like) and a Mg2+-containing PCR buffer, followed by
reaction at 72°C for 7 minutes. The PCR approach, conditions, etc. are described in, for
example, Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A
Compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley &
Sons (particularly, Chapter 15).

[0028]
Also, appropriate probes or primers can be prepared on the basis of information about
the nucleotide sequences of CAPRIN-1 gene and the amino acid sequences of CAPRIN-1
proteins, and used in the screening of, for example, a human cDNA library, to isolate the
desired DNA. Preferably, such a cDNA library is produced from cells, organs, or tissues
expressing proteins of CAPRIN-1. Examples of such cells or tissues include cells or tissues
derived from the testis or from cancers or tumors such as leukemia, breast cancer, lymphoma,
brain tumor, lung cancer, pancreatic cancer, and colorectal cancer. These operations,
including the preparation of probes or primers, the construction of a cDNA library, the
screening of the cDNA library, and the cloning of the gene of interest, are known to those
skilled in the art and can be performed according to methods described in, for example,
Sambrook et al., Molecular Cloning, the 2nd edition, Current Protocols in Molecular Biology
(1989), and Ausubel et al. (ibid.). DNAs encoding the human CAPRIN-1 proteins and the
partial peptides thereof can be obtained from the DNA thus obtained.
[0029]
The host cells into which the expression vectors are introduced may be any cell capable
of expressing the above polypeptides. Examples of prokaryotic cells include, but not limited
to, E. coli. Examples of eukaryotic cells include, but not limited to: mammalian cells such as
monkey kidney cells COS 1 and Chinese hamster ovary cells CHO; a human embryonic kidney
cell line HEK293; mouse embryonic skin cell line NIH3T3; yeast cells such as budding yeast
and fission yeast cells; silkworm cells; and Xenopus egg cells.
[0030]
In the case of using prokaryotic cells as the host cells, the expression vectors used may
have an origin that permits replication in the prokaryotic cells, a promoter, a ribosomal binding
site, a multicloning site, a terminator, a drug resistance gene, an auxotrophic complementary
gene, etc. Examples of expression vectors for E. coli can include pUC series, pBluescript II,
pET expression systems, and pGEX expression systems. The DNAs encoding the above
polypeptides can be incorporated into such expression vectors, with which prokaryotic host

cells are then transformed, followed by culture of the obtained transformants so that the
polypeptides encoded by the DNAs are expressed in the prokaryotic host cells. In this
respect, the polypeptides may be expressed as fusion proteins with other proteins.
[0031]
In the case of using eukaryotic cells as the host cells, expression vectors for eukaryotic
cells having a promoter, a splicing region, a poly(A) addition site, etc. may be used as the
expression vectors. Examples of such expression vectors can include pKAl, pCDM8,
pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV, pRS, pcDNA3, and pYES2 vectors. In
the same way as above, the DNAs encoding the above polypeptides can be incorporated into
such expression vectors, with which eukaryotic host cells are then transformed, followed by
culture of the obtained transformants so that the polypeptides encoded by the DNAs are
expressed in the eukaryotic host cells. In the case of using expression vectors such as
pIND/V5-His, pFLAG-CMV-2, pEGFP-Nl, or pEGFP-Cl, the polypeptides may be
expressed as various fusion proteins tagged with His tag (e.g., (His)6 to (His)io), FLAG tag,
myc tag, HA tag, GFP, or the like.
[0032]
The expression vectors can be introduced into the host cells using well known methods
such as electroporation, a calcium phosphate method, a liposome method, a DEAE dextran
method, microinjection, viral infection, lipofection, and binding with cell-penetrating peptides.
[0033]
The polypeptide of interest can be isolated and purified from the host cells by a
combination of separation operations known in the art. Examples thereof include, but not
limited to, treatment with a denaturant (e.g., urea) or a surfactant, ultrasonication, enzymatic
digestion, salting-out, solvent fractionation and precipitation, dialysis, centrifugation,
ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing electrophoresis, ion-exchange
chromatography, hydrophobic chromatography, affinity chromatography, and reverse-phase
chromatography.
[0034]

In order to prepare the antibody according to the present invention, antigens thus
prepared can be used as sensitizing antigens as described later.
[0035]

Antibodies (immunoglobulin) are usually heteromultimeric glycoproteins each
comprising at least two heavy chains and two light chains. The immunoglobulins, except for
IgM, are heterotetrameric glycoproteins of approximately 150 kDa each composed of two
identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is
connected to a heavy chain via a single covalent disulfide bond, though the number of
disulfide bonds between heavy chains varies among different immunoglobulin isotypes.
Each of the heavy and light chains also has an intrachain disulfide bond. Each heavy chain
has a variable domain (VH region) at one end, followed by a series of constant regions. Each
light chain has a variable domain (VL region) at one end and has a single constant region at
the other end. The light chain constant region is aligned with the first heavy chain constant
region, while the light chain variable domain is aligned with the heavy chain variable domain.
Particular regions called complementarity determining regions (CDRs) in the antibody
variable domains exhibit specific variability and impart binding specificity to the antibody.
Portions relatively conserved in the variable regions are called framework regions (FRs).
The complete heavy and light chain variable domains each comprise four FRs connected via
three CDRs. These three CDRs are called CDRH1, CDRH2, and CDRH3 in this order from
the N-terminus of the heavy chain. Likewise, the CDRs are called CDRL1, CDRL2, and
CDRL3 in the light chain. CDRH3 is most important for the binding specificity of the
antibody for its antigen. In addition, CDRs in each chain are kept close to each other by the
FR regions and contribute to the formation of an antigen-binding site in the antibody, together
with CDRs in the other chain. The constant regions do not directly contribute to antibody-
antigen binding, but exhibit various effector functions, for example, involvement in antibody-
dependent cellular cytotoxicity (ADCC), phagocytosis mediated by binding to an Fey receptor,

half-life/clearance rate mediated by a neonatal Fc receptor (FcRn), and complement-dependent
cytotoxicity (CDC) mediated by a Clq component in the complement cascade.
[0036]

The anti-CAPRIN-1 antibody according to the present invention means an antibody
having immunological reactivity with a full-length CAPRIN-1 protein or a fragment thereof.
Particularly, the anti-CAPPJN-l antibody of the present invention is an antibody
immunologically binding to a partial polypeptide of a CAPRIN-1 protein (partial CAPRIN-1
polypeptide) that is a peptide containing an epitope and consisting of the amino acid sequence
shown by SEQ ID NO: 5 or a polypeptide consisting of an amino acid sequence having 80%
or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or
higher sequence identity to the amino acid sequence. The antibody of the present invention
preferably recognizes an epitope consisting of approximately 7 to 12 consecutive amino acids,
for example, 8 to 11 consecutive amino acids, in the amino acid sequence shown by SEQ ID
NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more
preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid
sequence. This anti-CAPRIN-1 antibody of the present invention can specifically bind to the
full-length CAPRIN-1 protein. The antibody of the present invention can be obtained by
selecting an antibody immunologically binding to a polypeptide consisting of the amino acid
sequence shown by SEQ ID NO: 5 or a polypeptide consisting of an amino acid sequence
having 80% or higher, preferably 85% or higher, more preferably 90% or higher, further
preferably 95% or higher sequence identity to the amino acid sequence, according to a routine
method from among antibodies obtained with CAPRIN-1 proteins or fragments thereof as
antigens.
[0037]
In this context, the "immunological reactivity" means the property of the antibody
binding to the CAPRIN-1 antigen (a full-length CAPRIN-1 protein or a partial polypeptide
thereof) in vivo. Via such binding of the antibody of the present invention to the CAPRIN-1,

the antibody exerts the function of damaging (e.g., killing, suppressing, or regressing) tumor
cells. The antibody of the present invention can damage tumors such as breast cancer, kidney
cancer, pancreatic cancer, colorectal cancer (e.g. colon cancer), lung cancer, brain tumor,
gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma as a result
of binding to the CAPRTN-1 protein.
[0038]
The antibody of the present invention may be any type of antibody. Examples of the
type of the antibody according to the present invention include monoclonal antibodies,
polyclonal antibodies, synthetic antibodies, multispecific antibodies, human antibodies,
humanized antibodies, chimeric antibodies, single-chain antibodies, and antibody fragments
(e.g., Fab, F(ab')2, and Fv). Also, the antibody is any class of immunoglobulin molecule, for
example, IgG, IgE, IgM, IgA, IgD, or IgY, or any subclass, for example, IgGl, IgG2, IgG3,
IgG4, IgAl,orIgA2.
[0039]
Further the antibody may be modified by acetylation, formylation, amidation,
phosphorylation, PEGylation, or the like, as well as glycosylation.
[0040]
Hereinafter, preparation examples of various antibodies will be shown.
[0041]
When the antibody of the present invention is a monoclonal antibody, for example,
breast cancer cell lines SK-BR-3 expressing CAPRIN-1 is administered to each mouse for
immunization. The spleen is extracted from this mouse. After separation of spleen cells,
the cells are fused with mouse myeloma cells. Clones producing antibodies having a cancer
cell growth inhibitory effect are selected from among the obtained fusion cells (hybridomas).
Alternatively, clones producing antibodies binding to a polypeptide consisting of the amino
acid sequence shown by SEQ ID NO: 5 or a polypeptide consisting of an amino acid sequence
having 80% or higher sequence identity to the amino acid sequence may be selected. The

hybridomas producing monoclonal antibodies having a cancer cell growth inhibitory effect or
the hybridomas producing monoclonal antibodies against the polypeptides of SEQ ID NO: 5,
etc. are isolated and cultured. The antibody of the present invention can be prepared by
purification from the culture supernatant according to a general affinity purification method.
[0042]
The monoclonal antibody-producing hybridomas may be prepared, for example, as
follows. First, animals are immunized with sensitizing antigens according to a method known
in the art. This immunization method generally involves intraperitoneally or subcutaneously
injecting the sensitizing antigens to mammals. Specifically, the sensitizing antigens are
diluted with or suspended in PBS (phosphate-buffered saline), physiological saline, or the like
into an appropriate amount and then mixed, if desired, with an appropriate amount of a
conventional adjuvant, for example, a complete Freund's adjuvant. After emulsification, it is
administered to each mammal several times every 4 to 21 days. Alternatively, an appropriate
carrier may be used for the immunization with sensitizing antigens.
[0043]
After confirmation of a rise in the level of the desired antibody in the serum of the
animal (typically, mammal) thus immunized, immunocytes are collected from the animal and
subjected to cell fusion. Preferred examples of the immunocytes particularly include spleen
cells.
[0044]
Mammalian myeloma cells, for example, can be used as partner parent cells to be fused
with the immunocytes. Various cell lines known in the art, for example, P3U1 (P3-
X63Ag8Ul), P3 (P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.l
(Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler. G. and
Milstein, C. Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies. D.H. et al., Cell (1976)
8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (deSt. Groth, S.F. et
al., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I.S. J. Exp. Med. (1978) 148,

313-323), and R210 (Galfre, G. et al., Nature (1979) 277, 131-133), are preferably used as the
myeloma cells.
[0045]
The cell fusion between the immunocytes and the myeloma cells can be performed
basically according to a method known in the art, for example, the method of Kohler and
Milstein (Kohler, G. and Milstein, C. Methods Enzymol. (1981) 73, 3-46).
[0046]
More specifically, the cell fusion is carried out, for example, in the presence of a cell
fusion promoter in a conventional nutrient medium. For example, polyethylene glycol (PEG)
or hemagglutinating virus of Japan (HVJ) is used as the fusion promoter. If desired, an
auxiliary such as dimethyl sulfoxide may be further added in order to enhance fusion
efficiency.
[0047]
The ratio between the immunocytes and the myeloma cells used can be arbitrarily set.
For example, the amount of the immunocytes is preferably set to 1 to 10 times the amount of
the myeloma cells. Examples of the medium that can be used in the cell fusion include
RPMI1640 and MEM media suitable for the growth of the myeloma cell lines as well as
conventional media for use in this type of cell culture. In addition, a serum supplement such
as fetal calf serum (FCS) may be used in combination with these cells.
[0048]
For the cell fusion, the immunocytes and the myeloma cells are well mixed in a
predetermined amount of the medium. A PEG solution (average molecular weight: for
example, approximately 1000 to 6000) preheated to approximately 37°C is usually added to
the mixture at a concentration of 30 to 60% (w/v) and mixed therewith to form the hybridomas
of interest. Subsequently, procedures of sequentially adding an appropriate medium and
removing the supernatant by centrifugation are preferably repeated to remove cell fusion
agents or the like unfavorable for the growth of the hybridomas.
[0049]

The hybridomas thus obtained are cultured in a conventional selective medium, for
example, a HAT medium (medium containing hypoxanthine, aminopterin, and thymidine) for
selection. Culture in the HAT medium is continued for a period (usually, several days to
several weeks) sufficient for the death of cells (non-fused cells) other than the hybridomas of
interest. Subsequently, hybridomas producing the antibody of interest are screened for and
cloned as single clones by a conventional limiting dilution method.
[0050]
In addition to such obtainment of the hybridomas by the immunization of non-human
animals with antigens, hybridomas producing human antibodies having the desired activity
(e.g., cell growth inhibitory activity) may be obtained by sensitizing human lymphocytes, for
example, EB virus-infected human lymphocytes, with proteins, protein-expressing cells, or
lysates thereof in vitro and fusing the sensitized lymphocytes with human-derived myeloma
cells capable of dividing permanently, for example, U266 (Accession No. TIB 196).
[0051]
The monoclonal antibody-producing hybridomas thus prepared can be subcultured in a
conventional medium and can also be stored for a long period in liquid nitrogen.
[0052]
Specifically, the desired antigens or cells expressing the desired antigens are used as
sensitizing antigens in immunization according to a conventional immunization method. The
obtained irnmunocytes are fused with parent cells known in the art according to a conventional
cell fusion method. Monoclonal antibody-producing cells (hybridomas) can be screened for
by a conventional screening method to prepare the hybridomas producing monoclonal
antibodies of interest.
[0053]
Another example of the antibody that may be used in the present invention is a
polyclonal antibody. The polyclonal antibody can be obtained, for example, as follows:
[0054]

Serum is obtained from small animals such as mice, human antibody-producing mice,
or rabbits immunized with natural CAPRIN-1 proteins or recombinant CAPRIN-1 proteins
expressed as fusion proteins with GST or the like in microorganisms such as E. coli, or partial
peptides thereof. Alternatively, serum may be obtained from mammals immunized with
CAPRIN-1 fragment polypeptides each comprising the amino acid sequence shown by SEQ
ID NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more
preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid
sequence (preferably, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5),
or polypeptides each comprising (preferably, consisting of) an epitope consisting of
approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids,
in the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80%
or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or
higher sequence identity to the amino acid sequence, as sensitizing antigens. These serums
are purified using, for example, ammonium sulfate precipitation, protein A or protein G
columns, DEAE ion-exchange chromatography, or affinity columns coupled with CAPRIN-1
proteins or synthetic peptides to prepare the anti-CAPRIN-1 polyclonal antibody. The
polyclonal antibody of the present invention includes antibodies obtained from human
antibody-producing animals (e.g., mice) immunized with CAPRIN-1 proteins.
[0055]
In this context, for example, KM mice (Kirin Pharma Co., Ltd./Medarex) and Xeno
mice (Amgen Inc.) are known as the human antibody-producing mice (e.g., International
Publication Nos. WO02/43478 and WO02/092812). Complete human polyclonal antibodies
can be obtained from the blood of such mice immunized with CAPRIN-1 proteins or
fragments thereof. Alternatively, spleen cells may be isolated from the mice thus immunized
and fused with myeloma cells. In this way, human monoclonal antibodies can be obtained.
[0056]
The antigens can be prepared according to, for example, a method using animal cells
(JP Patent Publication (Kohyo) No. 2007-530068 A (2007)) or a method using baculovirus

(e.g., International Publication No. W098/46777). Antigens having low immunogenicity can
be bound to immunogenic macromolecules such as albumin for immunization. Antigens may
be administered with adjuvants for immunization.
[0057]
Alternatively, the antibody of the present invention may be obtained as recombinant
antibodies, which are produced using a genetic engineering technique which involves: cloning
the antibody genes from hybridomas; incorporating the antibody genes into appropriate
vectors; and introducing the vectors into hosts (see, e.g., Carl, A.K. Borrebaeck, James, W.
Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom
by MACMILLAN PUBLISHERS LTD, 1990). Specifically, antibody variable region (V
region) cDNAs are synthesized from the mRNAs of hybridomas using reverse transcriptase.
After obtainment of DNAs encoding the antibody V regions of interest, the DNAs are ligated
with DNAs encoding the desired antibody constant regions (C regions). The resulting
ligation products are incorporated into expression vectors. Alternatively, the antibody V
region-encoding DNAs may be incorporated into expression vectors containing antibody C
region DNAs. These DNAs are incorporated into the expression vectors so as to be
expressed under the control of expression control regions, for example, an enhancer and a
promoter. Next, host cells can be transformed with the resulting expression vectors and
allowed to express antibodies.
[0058]
The anti-CAPRIN-1 antibody of the present invention is preferably a monoclonal
antibody. Alternatively, the anti-CAPRIN-1 antibody of the present invention may be a
polyclonal antibody, a genetically engineered antibody (chimeric antibody, humanized
antibody, etc.), or the like.
[0059]
The monoclonal antibody includes human monoclonal antibodies, non-human animal
monoclonal antibodies (e.g., mouse, rat, rabbit, and chicken monoclonal antibodies), chimeric
monoclonal antibodies, and the like. The monoclonal antibody may be prepared by the

culture of hybridomas obtained by the fusion between spleen cells from non-human animals
(e.g., mice or human antibody-producing mice, chickens, and rabbits) immunized with
CAPRTN-1 proteins or fragments thereof and myeloma cells. Alternatively, genes of heavy
and light chain variable regions from the spleen cells of non-human animals (e.g., mice,
human antibody-producing mice, chickens, and rabbits) immunized with CAPRTN-1 proteins
or fragments thereof may be incorporated via linkers into phagemid vectors, which are then
introduced into E. coli so that single-chain antibodies are expressed via helper phages to
prepare the antibodies of interest. The chimeric antibody is an antibody prepared from a
combination of sequences derived from different animals and is, for example, an antibody
composed of mouse antibody heavy and light chain variable regions and human antibody
heavy and light chain constant regions. The chimeric antibody can be prepared using a
method known in the art which involves, for example: ligating DNAs encoding the antibody V
regions with DNAs encoding human antibody C regions; incorporating the resulting ligation
products into expression vectors; and introducing the vectors into hosts so that antibodies are
produced.
[0060]
Monoclonal antibodies that have immunological reactivity with a partial CAPRTN-1
polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 and have an
antitumor effect are prepared by methods described later in Examples. These monoclonal
antibodies each comprise, for example, a heavy chain variable (VH) region having the amino
acid sequence of SEQ ID NO: 9, 19, 58, 63, 69, or 77 and a light chain variable (VL) region
having the amino acid sequence of SEQ ID NO: 13, 23, 53, 62, 65, 73, or 81. In these
monoclonal antibodies, the VH region can comprise CDR1 shown by the amino acid sequence
of SEQ ID NO: 6, 16, 55, 66, or 74, CDR2 shown by the amino acid sequence of SEQ ID NO:
7, 17, 56, 67, or 75, and CDR3 shown by the amino acid sequence of SEQ ID NO: 8, 18, 57,
68, or 76, and the VL region can comprise CDR1 shown by the amino acid sequence of SEQ
ID NO: 10, 20, 50, 59, 70, or 78, CDR2 shown by the amino acid sequence of SEQ ID NO: 11,

21, 51, 60, 64, 71, or 79, and CDR3 shown by the amino acid sequence of SEQ ID NO: 12, 22,
52, 61, 72, or 80.
[0061]
The humanized antibody, also called reshaped human antibody, is an engineered
antibody. The humanized antibody is constructed by grafting antibody CDRs derived from
an immunized animal into the complementarity determining regions of a human antibody. A
general gene recombination approach therefor is also known.
[0062]
Specifically, for example, DNA sequences designed so as to link mouse, rabbit, and
chicken antibodies CDRs and human antibody framework regions (FRs) are synthesized by
PCR using several prepared oligonucleotides having terminal portions overlapping with each
other. The obtained DNAs are ligated with DNAs encoding human antibody constant
regions. Subsequently, the resulting ligation products are incorporated into expression
vectors, which are then introduced into hosts for antibody production to obtain the antibody of
interest (see European Patent Application Publication No. EP239400 and International
Publication No. WO96/02576). The human antibody FRs connected via CDRs are selected
such that the complementarity determining regions form a favorable antigen-binding site. If
necessary, amino acids in the framework regions of antibody variable regions may be
substituted such that the complementarity determining regions of the resulting reshaped human
antibody form an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53:
851-856). In addition, these framework regions may be replaced with framework regions
derived from various human antibodies (see International Publication No. W099/51743).
[0063]
The human antibody framework regions connected via CDRs are selected such that the
complementarity determining regions form a favorable antigen-binding site. If necessary,
amino acids in the framework regions of antibody variable regions may be substituted such
that the complementarity determining regions of the resulting reshaped human antibody form
an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53: 851-856).

[0064]
Amino acids in variable regions (e.g., FRs) or constant regions of the chimeric antibody
or the humanized antibody thus prepared may be substituted, for example, by other amino
acids.
[0065]
The amino acid substitution is the substitution of, for example, less than 15, less than
10, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less amino acids,
preferably 1 to 5 amino acids, more preferably 1 or 2 amino acids. The substituted antibody
should be functionally equivalent to an unsubstituted antibody. The substitution is desirably
conservative amino acid substitution, which is the substitution between amino acids similar in
properties such as charge, side chains, polarity, and aromaticity. The amino acids can be
classified in terms of similar properties into, for example: basic amino acids (arginine, lysine,
and histidine); acidic amino acids (aspartic acid and glutamic acid); uncharged polar amino
acids (glycine, asparagine, glutamine, serine, threonine, cysteine, and tyrosine); nonpolar
amino acids (leucine, isoleucine, alanine, valine, proline, phenylalanine, tryptophan, and
methionine); branched amino acids (threonine, valine, and isoleucine); and aromatic amino
acids (phenylalanine, tyrosine, tryptophan, and histidine).
[0066]
Examples of modified antibodies can include antibodies bound with various molecules
such as polyethylene glycol (PEG). In the modified antibody of the present invention, the
substance to be bound is not limited. In order to obtain such a modified antibody, the
obtained antibody can be chemically modified. A method therefor has already been
established in the art.
[0067]
In this context, the phrase "functionally equivalent" means that an antibody concerned
has biological or biochemical activity similar to that of the antibody of the present invention,
specifically, the antibody concerned has the function of damaging tumor and essentially causes

no rejection when applied to humans, for example. Examples of such activity can include
cell growth inhibitory activity and binding activity.
[0068]
A method for preparing a polypeptide functionally equivalent to a certain polypeptide,
which involves introducing a mutation into a polypeptide, is well known to those skilled in the
art. For example, those skilled in the art can introduce a mutation as appropriate into the
antibody of the present invention using site-directed mutagenesis (Hashimoto-Gotoh, T. et al.,
(1995) Gene 152, 271-275; Zoller, ML, and Smith, M. (1983) Methods Enzymol. 100, 468-
500; Kramer, W. et al., (1984) Nucleic Acids Res. 12, 9441-9456; Kramer, W. and Fritz, HJ.,
(1987) Methods Enzymol. 154, 350-367; Kunkel, TA., (1985) Proc. Natl. Acad. Sci. USA. 82,
488-492; and Kunkel (1988) Methods Enzymol. 85, 2763-2766) or the like, thereby prepare an
antibody functionally equivalent to the antibody of the present invention.
[0069]
An antibody that recognizes an epitope of a CAPRIN-1 protein described above or a
CAPRIN-1 polypeptide fragment including thereof can be obtained by a method generally
known to those skilled in the art. For example, the antibody can be obtained by a method
which involves determining the epitope of the CAPRIN-1 protein recognized by the anti-
CAPRIN-1 antibody having a cancer cell growth inhibitory effect obtained by the above by a
conventional method (e.g., epitope mapping or a method for identifying an epitope as
described later) and preparing an antibody using a polypeptide having an amino acid sequence
contained in the epitope as an immunogen, or a method which involves determining an epitope
for an antibody prepared by a conventional method and selecting an antibody that recognizes
the same epitope as that for the anti-CAPRIN-1 antibody. In this context, the "epitope" refers
to a polypeptide fragment having antigenicity or immunogenicity in mammals, preferably
humans. Its smallest unit consists of approximately 7 to 12 amino acids, preferably 8 to 11
amino acids.
[0070]

The antibody of the present invention is an antibody having immunological reactivity
with CAPRIN-1, an antibody specifically recognizing CAPRIN-1, or an antibody specifically
binding to CAPRIN-1 and exhibits cytotoxic activity or tumor growth inhibitory effect on
cancer. The antibody preferably has a structure that causes little or no rejection in recipient
animals. Examples of such antibodies include human antibodies, humanized antibodies,
chimeric antibodies (e.g., human-mouse chimeric antibodies), single-chain antibodies, and
bispecific antibodies when the recipient animals are humans. These antibodies have heavy
and light chain variable regions derived from a human antibody or have heavy and light chain
variable regions consisting of complementarity determining regions (CDR1, CDR2, and
CDR3) derived from a non-human animal antibody and framework regions derived from a
human antibody. Alternatively, these antibodies are recombinant antibodies having heavy
and light chain variable regions derived from a non-human animal antibody and heavy and
light chain constant regions derived from a human antibody. The antibody of the present
invention is preferably the former two antibodies.
[0071]
Such recombinant antibodies can be prepared as follows: DNAs encoding monoclonal
antibodies (e.g., human, mouse, rat, rabbit, and chicken monoclonal antibodies) against human
CAPRIN-1 are cloned from the antibody-producing cells such as hybridomas and used as
templates to prepare DNAs encoding the light and heavy chain variable regions of the
antibodies by RT-PCR or the like. The respective sequences of the light and heavy chain
variable regions and the respective sequences of CDR1, CDR2, and CDR3 in each region are
determined on the basis of the Kabat EU numbering system (Kabat et al., Sequences of
Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health,
Bethesda, Md. (1991)).
[0072]
A DNA encoding each variable region or a DNA encoding each CDR is prepared using
a genetic engineering technique (Sambrook et al., Molecular Cloning A Laboratory Manual,
Cold Spring Harbor Laboratory Press (1989)) or a DNA synthesizer. The above-mentioned

human monoclonal antibody-producing hybridomas can be prepared by immunizing human
antibody-producing animals (e.g., mice) with human CAPRJN-1 and then fusing spleen cells
excised from the immunized animals with myeloma cells. Separately, DNAs encoding light
or heavy chain variable and constant regions derived from a human antibody are prepared, if
necessary, using a genetic engineering technique or a DNA synthesizer.
[0073]
For the humanized antibody, a DNA encoding the humanized antibody can be prepared
by producing DNAs in which the CDR coding sequences in DNAs encoding a human
antibody-derived light or heavy chain variable regions are substituted by corresponding CDR
coding sequences of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived
antibody, ligating the resulting DNAs with the DNAs encoding human antibody-derived light
or heavy chain constant regions, respectively.
[0074]
For the chimeric antibody, a DNA encoding the chimeric antibody can be prepared by
ligating DNAs encoding light or heavy chain variable regions of a non-human animal (e.g.,
mouse, rat, rabbit, or chicken)-derived antibody with DNAs encoding human antibody-derived
light or heavy chain constant regions.
[0075]
The single-chain antibody means an antibody in which heavy and light chain variable
regions are linearly linked to each other via a linker. A DNA encoding the single-chain
antibody can be prepared by ligating a DNA encoding the heavy chain variable region, a DNA
encoding the linker, and a DNA encoding the light chain variable region. In this context, the
heavy and light chain variable regions are both derived from a human antibody or derived
from a human antibody in which CDRs alone are substituted by CDRs of a non-human animal
(e.g., mouse, rat, rabbit, or chicken)-derived antibody. The linker consists of 12 to 19 amino
acids. Examples thereof include (G4S)3 consisting of 15 amino acids (G.B. Kim et al.,
Protein Engineering Design and Selection 2007, 20 (9): 425-432).
[0076]

The bispecific antibody (diabody) means an antibody capable of specifically binding to
two different epitopes. A DNA encoding the bispecific antibody can be prepared by, for
example, ligating a DNA encoding a heavy chain variable region A, a DNA encoding a light
chain variable region B, a DNA encoding a heavy chain variable region B, and a DNA
encoding a light chain variable region A in this order, wherein the DNA encoding the light
chain variable region B and the DNA encoding the heavy chain variable region B are ligated
via a DNA encoding a linker as described above. In this context, the heavy and light chain
variable regions are all derived from a human antibody or derived from a human antibody in
which CDRs alone are substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or
chicken)-derived antibody.
[0077]
The recombinant DNAs thus prepared can be incorporated into one or more appropriate
vectors, which are then introduced into host cells (e.g., mammalian cells, yeast cells, and
insect cells), and the DNAs are (co)expressed to produce recombinant antibodies (see, P.J.
Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P.
Shepherd and C. Dean., Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS; and
J.W. Goding., Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).
[0078]
Examples of the antibody of the present invention prepared by any of the methods
described above include the following antibodies (a) to (g) obtained in Examples described
later:
(a) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising
complementarity determining regions of SEQ ID NOs: 10, 11, and 12 (e.g., an antibody
having a heavy chain variable region of SEQ ID NO: 9 and a light chain variable region of
SEQ ID NO: 13);
(b) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 16, 17, and 18 and a light chain variable region

comprising complementarity determining regions of SEQ ID NOs: 20, 21, and 22 (e.g., an
antibody constructed using a heavy chain variable region of SEQ ID NO: 19 and a light chain
variable region of SEQ ID NO: 23);
(c) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising
complementarity determining regions of SEQ ID NOs: 50, 51, and 52 (e.g., an antibody
constructed using a heavy chain variable region of SEQ ID NO: 9 and a light chain variable
regionofSEQIDNO:53);
(d) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region
comprising complementarity determining regions of SEQ ID NOs: 59, 60, and 61 (e.g., an
antibody constructed using a heavy chain variable region of SEQ ID NO: 58 and a light chain
variable region of SEQ ID NO: 62);
(e) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region
comprising complementarity determining regions of SEQ ID NOs: 59, 64, and 61 (e.g., an
antibody constructed using a heavy chain variable region of SEQ ID NO: 63 and a light chain
variable region of SEQ ID NO: 65);
(f) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 66, 67, and 68 and a light chain variable region
comprising complementarity determining regions of SEQ ID NOs: 70, 71, and 72 (e.g., an
antibody constructed using a heavy chain variable region of SEQ ID NO: 69 and a light chain
variable region of SEQ ID NO: 73);
(g) an antibody comprising a heavy chain variable region comprising complementarity
determining regions of SEQ ID NOs: 74, 75, and 76 and a light chain variable region
comprising complementarity determining regions of SEQ ID NOs: 78, 79, and 80 (e.g., an
antibody constructed using a heavy chain variable region of SEQ ID NO: 77 and a light chain
variable region of SEQ ID NO: 81);

[0079]
In this context, the amino acid sequences shown by SEQ ID NOs: 6, 7, and 8, and SEQ
ID NOs: 16, 17, and 18 correspond to CDR1, CDR2, and CDR3, respectively, of a mouse
antibody-derived heavy chain variable region. The amino acid sequences shown by SEQ ID
NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, and SEQ ID NOs: 50, 51, and 52
correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody-derived light chain
variable region. The amino acid sequences shown by SEQ ID NOs: 55, 56, and 57, SEQ ID
NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76 correspond to CDR1, CDR2, and
CDR3, respectively, of a chicken antibody-derived heavy chain variable region. The amino
acid sequences shown by SEQ ID NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID
NOs: 70, 71, and 72, and SEQ ID NOs: 78, 79, and 80 correspond to CDR1, CDR2, and
CDR3, respectively, of a chicken antibody-derived light chain variable region.
[0080]
Examples of the humanized antibody, the chimeric antibody, the single-chain antibody,
or the bispecific antibody of the present invention include antibodies described below. The
following antibodies are illustrative embodiments of the antibody (a), but there may be also
similar embodiments of the other antibodies (b) to (g).
[0081]
(i) an antibody comprising a heavy chain variable region comprising the amino acid
sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-
derived framework regions and a light chain variable region comprising the amino acid
sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-
derived framework regions.
[0082]
(ii) an antibody comprising a heavy chain variable region comprising the amino acid
sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-
derived framework regions, a heavy chain constant region comprising a human antibody-
derived amino acid sequence, a light chain variable region comprising the amino acid

sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-
derived framework regions, and a light chain constant region comprising a human antibody-
derived amino acid sequence.
[0083]
(iii) an antibody comprising a heavy chain variable region comprising the amino acid
sequence of SEQ ID NO: 9, a heavy chain constant region comprising a human antibody-
derived amino acid sequence, a light chain variable region comprising the amino acid
sequence of SEQ ID NO: 13, and a light chain constant region comprising a human antibody-
derived amino acid sequence.
[0084]
The sequences of the constant and variable regions of human antibody heavy and light
chains are available from, for example, NCBI (USA; GenBank, UniGene, etc.). For example,
the following sequences can be referred to: Accession No. J00228 for a human IgGl heavy
chain constant region; Accession No. J00230 for a human IgG2 heavy chain constant region;
Accession No. X03604 for a human IgG3 heavy chain constant region; Accession No. K01316
for a human IgG4 heavy chain constant region; Accession Nos. V00557, X64135, and X64133
for a human light chain K constant region; and Accession Nos. X64132 and X64134 for a
human light chain X constant region.
[0085]
Preferably, these antibodies have cytotoxic activity and can thereby exert an antitumor
effect.
[0086]
The above particular sequences of the heavy and light chain variable regions and CDRs
in the above-mentioned antibodies are provided merely for illustrative purposes, and it is clear
that the antibody of the present invention is not limited by the particular sequences.
Hybridomas capable of producing anti-human CAPRJN-1 human antibodies or non-human
animal antibodies (e.g., mouse antibodies) different from those specifically described above
are prepared, and monoclonal antibodies produced by the hybridomas are recovered and it is

determined whether or not the recovered antibodies are the antibodies of interest using the
immunological binding activity against human CAPRIN-1 and cytotoxic activity as indicators.
The monoclonal antibody-producing hybridomas of interest are thereby identified. Then,
DNAs encoding heavy and light chain variable regions of the antibodies of interest are
prepared from the hybridomas and sequenced, as described above. The DNAs are used for
the preparation of different antibodies.
[0087]
The antibody described above may be any of the antibodies (a) to (g), etc. having the
substitution, deletion, or addition of one or several amino acids, in particular, in a region other
than CDRs, for example, in a framework region sequence and/or a constant region sequence,
as long as the antibody has such specificity that it can specifically recognize CAPRIN-1.
Herein, the term "several" preferably means 2 to 5, more preferably 2 or 3.
[0088]
The antibody of the present invention has an affinity constant Ka (kon/koff) of preferably
at least 107 M"1, at least 108 M"1, at least 5 x 108 M"1, at least 109 M"1, at least 5 x 109 M"1, at
least 1010 M"1, at least 5 x 1010 NT1, at least 1011 M"1, at least 5 x 1011 M"1, at least 1012 M"1, or
at least 1013 M"1 for the CAPRIN-1 protein or the fragment thereof.
[0089]
The antibody of the present invention can be conjugated with an antitumor agent. The
conjugation of the antibody with the antitumor agent can be performed via a spacer having a
group reactive with an amino group, a carboxyl group, a hydroxy group, a thiol group, or the
like (e.g., a succinimidyl group, a formyl group, a 2-pyridyldithio group, a maleimidyl group,
an alkoxycarbonyl group, or a hydroxy group).
[0090]
Examples of the antitumor agent include the following antitumor agents known by
literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-
fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa,
uredopa, altretamine, triethylenemelamine, triethylenephosphoramide,

triethylenethiophosphoramide, trimethylolomelamine, bullatacin, bullatacinone, camptothecin,
bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin,
pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide,
estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin,
clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin,
cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin,
detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin,
marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin,
potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,
ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-
mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur,
cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens (e.g.,
calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone),
aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside,
aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine,
demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone, etoglucid, lentinan,
lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine,
pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide,
procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone,
roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol,
mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine,
mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide,
mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin,
aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors,
difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable
salts and derivatives thereof.

[0091]
Alternatively, the antibody of the present invention can be administered in combination
with an antitumor agent to produce a higher therapeutic effect. This approach is adaptable to
a patient with a cancer expressing CAPRIN-1 either before or after surgical operation. This
approach can be applied, particularly after surgery, to CAPRIN-1-expressing cancer, which
has been treated conventionally with an antitumor agent alone, to produce higher prevention of
cancer recurrence or prolongation of survival time.
[0092]
Examples of the antitumor agent used in the combined administration with the antibody
of the present invention include the following antitumor agents known by literatures, etc.:
paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil,
thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa,
altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide,
trimethylolomelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin,
cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin, pancratistatin,
sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine,
ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate,
esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin,
carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-
oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin
C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin,
zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine,
thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol,
mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone,

aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene,
edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone,
etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone,
mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid,
2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium,
tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine,
mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil,
gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine,
etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide,
edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase
inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically
acceptable salts (known in the art) and derivatives (known in the art) thereof. Of these
antitumor agents, cyclophosphamide, paclitaxel, docetaxel, or vinorelbine is particularly
preferably used.
[0093]
The antibody of the present invention may be bound to a radioisotope known by
literatures, etc., such as 211At, 131I, 125I, 90Y, 186Re, 188Re, 153Sm, 212Bi, 32P, 175Lu, or 176Lu.
Preferably, a radioisotope effective for the treatment or diagnosis of tumor is used. Such a
radioisotope is also included in the scope of the antitumor agent according to the present
invention.
[0094]
identification of epitope>
The antibody of the present invention recognizes the amino acid sequence shown by
SEQ ID NO: 5 as an epitope, as shown below in Examples. One example of a method for
confirming the epitope for the antibody of the present invention comprises immobilizing the
polypeptide of SEQ ID NO: 5 (epitope) onto a plate and evaluating the antibody for its
reactivity against this epitope. Specifically, the polypeptide of SEQ ID NO: 5 is immobilized
onto a plate through reaction with an electrophilic functional group attached via a spacer of

e.g., oligoethylene glycol to the plate, and then reacted with the antibody of the present
invention. For example, a HRP (horseradish peroxidase)-labeled secondary antibody capable
of binding to the antibody of the present invention can be reacted therewith to evaluate the
reactivity of the antibody (to confirm the epitope for the antibody of the present invention).
The polypeptide of SEQ ID NO: 5 to be immobilized on a plate may be used as a form
consisting of the sequence of SEQ ID NO: 5 or a partially modified form (e.g., a modified
form of the polypeptide at the N- or C-terminal residue with any several amino acids or a
protein such as KLH or a modified form of the polypeptide with a MAP protein), as long as
the antibody of the present invention binds to these polypeptide forms.
[0095]
Some antibodies of the present invention may not react with the polypeptide of SEQ ID
NO: 5 (i.e., the epitope not being confirmed) in the above method. In such a case, the epitope
for the antibody of the present invention can be confirmed by reacting the antibody with the
antigen under solution conditions that facilitate antigen-antibody binding as described in
Example 2, obtaining the resulting antigen-antibody complex by an immunoprecipitation
method, and then separating a polypeptide moiety bound to the antibody, and determining its
amino acid sequence. The antigen may be a polypeptide consisting of the sequence of SEQ
ID NO: 5, its partially modified one, or a CAPRIN-1 protein as long as an epitope reactive
with the antibody of the present invention can be confirmed therefor by the above-mentioned
methods.
[0096]

It is considered that the antitumor effect of the anti-CAPRIN-1 antibody to be used in
the present invention on CAPRIN-1-expressing cancer cells is brought about by the following
mechanism: Antibody-dependent effector cell-mediated cytotoxicity (ADCC) against the
CAPRIN-1-expressing cells and complement-dependent cytotoxicity (CDC) against the
CAPRIN-1-expressing cells. However, the scope of the present invention is not intended to
be limited by the mechanism.

[0097]
The antitumor effect based on the mechanism is known to correlate with the number of
antibody-binding target molecules expressed on the surface of cancer cells (Niwa R., Clinical
Cancer Research (2005) Mar 15; 11 (6): 2327-2336). The number of target molecules
expressed on the surface of cancer cells can be examined using an existing assay kit capable of
measuring the number of molecules on cell surface. Specifically, the number of antibody-
binding target molecules can be determined by: reacting cancer cells with, for example,
antibodies against the target molecules as primary antibodies; reacting therewith fluorescently
labeled antibodies against the primary antibodies, together with calibration curve beads with
the preliminarily known number of molecules; measuring the mean fluorescence intensity of
the samples; and determining the number of the target molecules on the basis of the obtained
calibration curve.
[0098]
Thus, the anti-CAPRIN-1 antibody to be used in the present invention can be assayed
for its activity by determining ex vivo the ADCC activity or the CDC activity against
CAPRIN-1-expressing cancer cells or by examining the number of CAPRIN-1 molecules
expressed on the surface of cancer cells in the case of using the anti-CAPRIN-1 antibody
according to the present invention as a primary antibody as specifically shown below in
Examples.
[0099]
The anti-CAPRIN-1 antibody to be used in the present invention binds to CAPRIN-1
proteins on cancer cells and exhibits an antitumor effect through the activity. Thus, the anti-
CAPRIN-1 antibody of the present invention is considered to be useful in the treatment or
prevention of cancer. Specifically, the present invention provides a pharmaceutical
composition for treatment and/or prevention of cancer, comprising the anti-CAPRIN-1
antibody as an active ingredient. The anti-CAPRIN-1 antibody to be used for the purpose of
administration to human bodies (antibody therapy) is preferably a human antibody or a
humanized antibody for reducing immunogenicity.

[0100]
The anti-CAPRIN-1 antibody with higher binding affinity for a CAPRIN-1 protein on
the surface of cancer cells exerts stronger antitumor activity. Thus, the antibody according to
the present invention can be expected to have a stronger antitumor effect due to the high
binding affinity for the CAPRIN-1 protein, and therefore it can be used as a pharmaceutical
composition for use in the treatment and/or prevention of cancer. Preferably, the antibody
according to the present invention has high binding affinity with association constant (affinity
constant) Ka (kon/koff) of preferably at least 107 M"1, at least 108 M"1, at least 5 x 108 M"1, at
least 109 M"1, at least 5 x 109 M"1, at least 1010 M"1, at least 5 x 1010 M"1, at least 1011 M"1, at
least 5 x 1011 M"1, at least 1012 M"', or at least 1013 M"1, as described above.
[0101]
A larger number of CAPRIN-1 molecules that can bind to anti-CAPRTN-1 antibodies
on the surface of cancer cells produces stronger antitumor activity. Desirably, in order to
produce the expected antitumor effect, the number of CAPRIN-1 molecules to which the
antibodies bind is 104 or more, preferably 105 or more CAPRIN-1 molecules per cancer cell,
as measured using the anti-CAPRIN-1 antibody of the present invention. Tumor (cancer
cells) having a large number of CAPRIN-1 molecules on its cell surface is particularly
preferred as cancer subject to the administration of the antibody of the present invention.
[0102]

The ability of the antibody to bind to CAPRIN-1 can be determined by use of binding
assay using, for example, ELISA, Western blot, immunofluorescence, and flow cytometry
analysis, as described in Examples.
[0103]

The antibody that recognizes CAPRIN-1 can be tested for its reactivity with CAPRIN-1
by an immunohistochemical method well known to those skilled in the art using a
paraformaldehyde- or acetone-fixed frozen section or paraformaldehyde-fixed paraffin-

embedded tissue section of a tissue obtained from a patient during surgical operation or from a
xenograft tissue-carrying animal inoculated with a cell line expressing CAPRJN-1 either
spontaneously or after transfection.
[0104]
For immunohistochemical staining, the antibody reactive with CAPRJN-1 can be
stained by various methods. For example, the antibody can be visualized through reaction
with a horseradish peroxidase-conjugated goat anti-mouse antibody, goat anti-rabbit antibody,
or goat anti-chicken antibody.
[0105]
Pharmaceutical composition, and method for treating and/or preventing cancer>
A target of the pharmaceutical composition for treatment and/or prevention of cancer of
the present invention is not particularly limited as long as the target is cancer (cells) expressing
a CAPRJN-1 gene.
[0106]
The terms "tumor" and "cancer" used herein mean malignant neoplasm and are used
interchangeably with each other.
[0107]
The cancer targeted in the present invention is cancer expressing a CAPRJN-1 protein-
encoding gene and is preferably breast cancer, kidney cancer, pancreatic cancer, colorectal
cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate
cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma,
mastocytoma, or melanoma.
[0108]
Specific examples of these cancers include, but not limited to, breast adenocarcinoma,
complex-type breast adenocarcinoma, malignant mixed tumor of mammary gland, intraductal
papillary adenocarcinoma, lung adenocarcinoma, squamous cell cancer, small-cell cancer,
large-cell cancer, glioma which is tumor of neuroepithelial tissue, ventricular ependymoma,
neuronal tumor, embryonal neuroectodermal tumor, neurilemmoma, neurofibroma,

meningioma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma,
alimentary lymphoma, small to medium cell-type lymphoma, cecal cancer, ascending colon
cancer, descending colon cancer, transverse colon cancer, sigmoid colon cancer, rectal cancer,
epithelial ovarian cancer, germ cell tumor, stromal cell tumor, pancreatic ductal carcinoma,
invasive pancreatic ductal carcinoma, pancreatic adenocarcinoma, acinar cell carcinoma,
adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm,
mucinous cystic neoplasm, pancreatoblastoma, serous cystadenocarcinoma, solid papillary
tumor, gastrinoma, glucagonoma, insulinoma, multiple endocrine neoplasia type-1 (Wermer's
syndrome), nonfunctional islet cell tumor, somatostatinoma, and VIPoma.
[0109]
The subject (patient) as the recipient is preferably mammals, for example, mammals
including primates, pet animals, livestock, and sport animals, and particularly preferably
humans, dogs, and cats.
[0110]
When using the antibody of the present invention in a pharmaceutical composition, the
pharmaceutical composition can be formulated by a method known to those skilled in the art.
For example, the pharmaceutical composition can be used in the form of a parenteral injection
of an aseptic solution or suspension with water or any other pharmaceutically acceptable liquid.
For example, the pharmaceutical composition may be formulated with the antibody mixed in a
unit dosage form required for generally accepted pharmaceutical practice, in combination with
pharmacologically acceptable carriers or media, specifically, sterilized water, physiological
saline, plant oil, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent,
an excipient, a vehicle, a preservative, a binder, etc, as appropriate. The amount of the active
ingredient in such a preparation is determined such that an appropriate dose within the
indicated range can be achieved.
[0111]
An aseptic composition for injection can be formulated according to conventional
pharmaceutical practice using a vehicle such as injectable distilled water.

[0112]
Examples of aqueous solutions for injection include physiological saline, isotonic
solutions containing glucose and other adjuvants, for example, D-sorbitol, D-mannose, D-
mannitol, and sodium chloride. These solutions may be used in combination with an
appropriate solubilizer, for example, an alcohol (particularly, ethanol) or a polyalcohol (e.g.,
propylene glycol and polyethylene glycol), or a nonionic surfactant, for example, polysorbate
80 (TM) or HCO-60.
[0113]
Examples of oily solutions include those using sesame oil or soybean oil. The
solutions may be used in combination with a solubilizer such as benzyl benzoate or benzyl
alcohol. A buffer (e.g., a phosphate buffer solution or a sodium acetate buffer solution), a
soothing agent (e.g., procaine hydrochloride), a stabilizer (e.g., benzyl alcohol or phenol), or
an antioxidant may be added to the solutions. The injection solutions thus prepared are
generally charged into appropriate ampules.
[0114]
The pharmaceutical composition of the present invention is administered orally or
parenterally, preferably parenterally. Specific examples of its dosage forms include
injections, intranasal administration agents, transpulmonary administration agents, and
percutaneous administration agents. Examples of the injections include intravenous injection,
intramuscular injection, intraperitoneal injection, and subcutaneous injection, through which
the pharmaceutical composition can be administered systemically or locally.
[0115]
Also, the administration method can be appropriately selected depending on the age,
weight, sex, symptoms, etc. of a patient. The dose of a pharmaceutical composition
containing the antibody or a polynucleotide encoding the antibody can be selected within a
range of, for example, 0.0001 to 1000 mg/kg of body weight per dose. Alternatively, the
dose can be selected within a range of, for example, 0.001 to 100000 mg/body of a patient,
though the dose is not necessarily limited to these numeric values. Although the dose and the

administration method vary depending on the weight, age, sex, symptoms, etc. of a patient,
those skilled in the art can appropriately select the dose and the method.
[0116]
The pharmaceutical composition including the antibody of the present invention or
fragments thereof can be administered to a subject to treat and/or prevent cancer, preferably
breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor,
gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
[0117]
The present invention further encompasses a method for treating and/or preventing
cancer, comprising administering the pharmaceutical composition of the present invention in
combination with the antitumor agent as exemplified above or a pharmaceutical composition
comprising the antitumor agent to a subject. The antibody of the present invention or the
fragment thereof may be administered simultaneously with or separately from the antitumor
agent to the subject. In the case of separately administering these pharmaceutical
compositions, either one may be administered first or later. Their dosing intervals, doses,
administration routes, and the number of doses can be appropriately selected by a specialist.
The other pharmaceutical dosage forms to be administered simultaneously also include, for
example, pharmaceutical compositions formulated by mixing the antibody of the present
invention or the fragment thereof or the antitumor agent into a pharmacologically acceptable
carrier (or medium). The above descriptions about composition, formulation, administration
routes, doses, cancer, etc. as to the pharmaceutical compositions and dosage forms containing
the antibody of the present invention are also applicable to any of the above-mentioned
pharmaceutical compositions and dosage forms containing the antitumor agent.
[0118]
Thus, the present invention also provides a pharmaceutical combination for treatment
and/or prevention of cancer, comprising the pharmaceutical composition of the present
invention and a pharmaceutical composition comprising the antitumor agent as exemplified

above, and a method for treating and/or preventing cancer, comprising administering thereof.
The present invention also provides a pharmaceutical composition for treatment and/or
prevention of cancer, comprising the antibody or the fragment thereof of the present invention
and the antitumor agent together with a pharmacologically acceptable carrier.
[0119]
Polypeptide and DNA>
The present invention further provides a DNA encoding the antibody of the present
invention or the fragment (antibody-binding fragment) thereof. The DNA may be a DNA
encoding the heavy and/or light chains of the antibody or may be a DNA encoding the heavy
and/or light chain variable regions of the antibody. The DNA may also be a DNA encoding
each or a combination of the complementarity determining regions of antibody. Such a DNA
includes, for example, a heavy chain variable region-encoding DNA comprising nucleotide
sequences encoding the amino acid sequences of SEQ ID NOs: 6, 7, and 8, and a light chain
variable region-encoding DNA comprising nucleotide sequences encoding the amino acid
sequences of SEQ ID NOs: 10, 11, and 12, in the case of the above-mentioned antibody (a).
[0120]
The complementarity determining regions (CDRs) encoded by the DNA having these
sequences serve as regions that determine the specificity of the antibody. Sequences
encoding the other regions (i.e., constant regions and framework regions) of the antibody may
therefore be sequences derived from other antibodies. In this context, "other antibodies" also
include antibodies derived from non-human organisms, but are preferably those derived from
humans from the viewpoint of reducing adverse reactions. Specifically, in the DNA of the
present invention, regions encoding each framework region and each constant region in the
heavy and light chains preferably comprise nucleotide sequences encoding corresponding
human antibody-derived amino acid sequences.
[0121]
Further examples of the DNA encoding the antibody of the present invention include a
DNA encoding a heavy chain variable region comprising a nucleotide sequence encoding the

amino acid sequence of SEQ ID NO: 9, and a DNA encoding a light chain variable region
comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 13, in the
case of the above-mentioned antibody (a). In this context, an example of nucleotide
sequences encoding the amino acid sequence of SEQ ID NO: 9 is the nucleotide sequence of
SEQ ID NO: 14. An example of nucleotide sequences encoding the amino acid sequence of
SEQ ID NO: 13 is the nucleotide sequence of SEQ ID NO: 15. When such a DNA comprises
regions encoding constant regions of the heavy and light chains, each of the regions preferably
comprises a nucleotide sequence encoding a corresponding human antibody-derived amino
acid sequence (amino acid sequence of each constant region of the heavy and light chains).
[0122]
These antibody DNAs can be obtained, for example, by the methods described above,
or the following method. First, total RNAs are prepared from hybridomas producing the
antibody of the present invention using a commercially available RNA extraction kit, and
cDNAs are synthesized therefrom using reverse transcriptase and random primers or the like.
Subsequently, the antibody-encoding cDNAs are amplified by PCR using oligonucleotide
primers for conserved sequences of variable regions in known mouse antibody heavy or light
chain genes. Sequences encoding the constant regions can be obtained by PCR amplification
of the known sequences. The nucleotide sequence of the DNA can be incorporated into a
plasmid or a phage for sequencing, for example, and determined according to a conventional
method.
[0123]
The present invention further provides the following polypeptides and DNAs related to
the above-mentioned antibodies (a) to (g):
(i) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 9, 19, 58,
63, 69, and 77, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the
nucleotide sequences of SEQ ID NOs: 14 and 24);

(ii) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 13, 23, 53,
62, 65, 73, and 81, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the
nucleotide sequences of SEQ ID NOs: 15, 25, and 54);
(iii) heavy chain CDR polypeptides selected from the group consisting of amino acid
sequences shown by SEQ ID NOs: 6, 7, and 8, SEQ ID NOs: 16, 17, and 18, SEQ ID NOs: 55,
56, and 57, SEQ ID NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76, and a DNA
encoding the polypeptides; and
(iv) light chain CDR polypeptides selected from amino acid sequences shown by SEQ
ID NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, SEQ ID NOs: 50, 51, and 52, SEQ ID
NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID NOs: 70, 71, and 72, and SEQ ID
NOs: 78, 79, and 80, and a DNA encoding the polypeptides.
[0124]
These polypeptides and DNAs can be prepared using genetic engineering techniques as
described above.
[0125]

The aspects of the present invention described above are summarized below.
[0126]
(1) An antibody or a fragment thereof which has immunological reactivity with a
partial CAPRTN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5
or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.
[0127]
(2) The antibody or the fragment thereof according to (1), wherein the antibody or the
fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRTN-1 protein.
[0128]
(3) The antibody or the fragment thereof according to (1) or (2), wherein the antibody
is a monoclonal antibody or a polyclonal antibody.
[0129]

(4) The antibody or the fragment thereof according to any of (1) to (3), wherein the
antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain
antibody, or a multispecific antibody.
[0130]
(5) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 10, 11, and 12 and has immunological reactivity with the
CAPRIN-1 protein.
[0131]
(6) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 20, 21, and 22 and has immunological reactivity with the
CAPRIN-1 protein.
[0132]
(7) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 50, 51, and 52 and has immunological reactivity with the
CAPRIN-1 protein.
[0133]
(8) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 59, 60, and 61 and has immunological reactivity with the
CAPRIN-1 protein.
[0134]

(9) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 59, 64, and 61 and has immunological reactivity with the
CAPRIN-1 protein.
[0135]
(10) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 70, 71, and 72 and has immunological reactivity with the
CAPRTN-1 protein.
[0136]
(11) The antibody or the fragment thereof according to any of (1) to (4), which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 78, 79, and 80 and has immunological reactivity with the
CAPRIN-1 protein.
[0137]
(12) The antibody or the fragment thereof according to any of (1) to (11), wherein the
antibody or the fragment thereof is -conjugated with an antitemor agent.
[0138]
(13) A pharmaceutical composition for treatment and/or prevention of cancer,
comprising the antibody or the fragment thereof according to any of (1) to (12) as an active
ingredient.
[0139]
(14) The pharmaceutical composition according to (13), wherein the cancer is breast
cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric

cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
[0140]
(15) A pharmaceutical combination for treatment and/or prevention of cancer,
comprising the pharmaceutical composition according to (13) or (14) and a pharmaceutical
composition comprising an antitumor agent.
[0141]
(16) A DNA encoding the antibody or the fragment thereof according to any of (1) to
(11).
[0142]
(17) A method for treating and/or preventing cancer, comprising administering the
antibody or the fragment thereof according to any of (1) to (12), the pharmaceutical
composition according to (13) or (14), or the pharmaceutical combination according to (15), to
a subject.
Examples
[0143]
Hereinafter, the present invention will be described specifically with reference to
Examples. However, the scope of the present invention is not intended to be limited by these
specific examples.
[0144]
Example 1 Analysis of CAPRIN-1 expression in each tissue
CAPRIN-1 gene expression in canine and human normal tissues and various cell lines
was examined by RT-PCR according to Example 1(4) of WO2010/016526. As a result,
strong expression was observed in the testis among the healthy canine tissues, whereas
expression was observed in canine breast cancer and adenocarcinoma tissues. Further, as a
result of examining the expression in human tissues, the expression was observed only in the
testis among normal tissues, as with the canine CAPRIN-1 gene. By contrast, the expression

was detected in many types of cancer cell lines, including 8 human breast cancer cell lines
(ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1)
and 4 pancreatic cancer cell lines (Capan-2, MIAPaCa-2, Panc-1, and BxPc-3), among cancer
cells. These results demonstrated that CAPRIN-1 expression is not found in normal tissues
other than the testis, whereas CAPRIN-1 is expressed in the breast cancer cell lines and the
pancreatic cancer cell lines.
[0145]
Example 2 Preparation of mouse monoclonal antibody against CAPRJN-1
(1) Preparation of mouse monoclonal antibody #1
100 p.g of human CAPRIN-1 proteins (having the amino acid sequence of SEQ ID NO:
2) prepared in Example 3 of WO2010/016526 was mixed with an equal amount of
MPL+TDM adjuvant (Sigma-Aldrich Corp.). This mixture was used as an antigen solution
per mouse. The antigen solution was intraperitoneally administered to each 6-week-old
Balb/c mouse (prepared by Japan SLC, Inc.). Then, 7 administrations were performed every
1 week to complete immunization. Three days after the final immunization, the spleen of
each mouse was excised and ground between two sterilized glass slides. Procedures of
washing with PBS(-) (manufactured by Nissui Pharmaceutical Co., Ltd.) and centrifuging at
1500 rpm for 10 minutes to remove the supernatant were repeated three times to obtain spleen
cells. The obtained spleen cells were mixed with mouse myeloma cells SP2/0 (purchased
from ATCC) at a ratio of 10:1. A PEG solution prepared by mixing 200 ul of an RPMI1640
medium containing 10% FBS, which was heated to 37°C, with 800 ul of PEG1500
(manufactured by Boehringer Ingelheim GmbH) was added to the cell mixture, and then it was
left to stand for 5 minutes for cell fusion. After removal of the supernatant via centrifugation
at 1700 rpm for 5 minutes, the cells were suspended in 150 ml of an RPMI1640 medium
containing 15% FBS supplemented with 2% equivalent of a HAT solution (Gibco) (HAT
selective medium). This suspension was seeded onto fifteen 96-well plates (Nunc) at 100
ul/well. The spleen cells and the myeloma cells were fused by culturing for 7 days at 37°C,
5% CO2 to obtain hybridomas.

[0146]
The prepared hybridomas were screened for the binding affinity of antibodies produced
by the hybridomas against CAPRTN-1 proteins as an indicator. A 1 ug/ml solution of the
CAPRTN-1 protein prepared in Example 3 of WO2010/016526 was added to a 96-well plate at
100 ul/well and left to stand at 4°C for 18 hours. Each well was washed three times with
PBS-T. Then, a 0.5% bovine serum albumin (BSA) solution (manufactured by Sigma-
Aldrich Corp.) was added thereto at 400 ul/well and left to stand at room temperature for 3
hours. The solution in each well was removed, and each well was washed three times with
400 ul of PBS-T. Then, the culture supernatant of each hybridoma obtained above was
added thereto at 100 ul/well and left to stand at room temperature for 2 hours. Each well was
washed three times with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies
(manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100
ul/well and left to stand at room temperature for 1 hour. Each well was washed three times
with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific
Inc.) was added thereto at 100 ul/well and left to stand for 15 to 30 minutes to cause color
reaction. After the color development, the reaction was terminated by the addition of IN
sulfuric acid at 100 ul/well. The absorbance was measured at 450 nm and 595 nm using an
absorption spectrometer. As a result, several hybridomas producing antibodies having high
absorbance were selected.
[0147]
The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in
the plate. One week later, hybridomas forming single colonies in the wells were observed.
The cells in these wells were further cultured, and the cloned hybridomas were screened for
the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1 protein as an
indicator. A 1 ug/ml solution of the CAPPJN-1 protein prepared in Example 3 of
WO2010/016526 was added to a 96-well plate at 100 ul/well and left to stand at 4°C for 18
hours. Each well was washed three times with PBS-T. Then, a 0.5% BSA solution was
added thereto at 400 ul/well and left to stand at room temperature for 3 hours. The solution

in each well was removed, and each well was washed three times with 400 (J.1 of PBS-T.
Then, the culture supernatant of each hybridoma obtained above was added thereto at 100
ul/well and left to stand at room temperature for 2 hours. Each well was washed three times
with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by
Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100 ul/well and left to
stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then,
a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto
at 100 ul/well and left to stand for 15 to 30 minutes to cause color reaction. After the color
development, the reaction was terminated by the addition of IN sulfuric acid at 100 ul/well.
The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a
result, 88 hybridoma lines producing monoclonal antibodies reactive with the CAPRTN-1
protein were obtained.
[0148]
Next, these monoclonal antibodies were screened for antibodies reactive with the
surface of breast cancer cells expressing CAPRIN-1. Specifically, 106 cells of a human
breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube.
100 ul of the culture supernatant of the hybridoma obtained above was added thereto and left
to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG
antibodies (manufactured by Invitrogen Corp.) diluted 500-fold with PBS containing 0.1%
FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the
fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company).
On the other hand, the same operation as above was performed using the serum of each
untreated 6-week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture,
instead of the antibodies, to prepare a control. As a result, one monoclonal antibody (#1)
having stronger fluorescence intensity than that of the control, i.e., reactive with the surface of
the breast cancer cells, was selected.
[0149]

(2) Identification of CAPRIN-1 epitope recognized by anti-CAPRIN-1 monoclonal
antibody #1
The cancer cell surface-reactive anti-CAPRIN-1 monoclonal antibody #1 obtained in
the section (1) was used to identify a CAPRIN-1 epitope region recognized thereby. 100 ug
of recombinant CAPRIN-1 proteins was dissolved in a protein inhibitor-free dissolution buffer
and reacted with the mouse monoclonal antibody #1. A digestive enzyme trypsin or
chymotrypsin was added to the solution to perform digestion reaction at an adequate
temperature. After the reaction, a protein G Sepharose carrier was added to the reaction
mixture, reacted therewith, and precipitated by centrifugation. After removal of the
supernatant, the carrier was washed with a dissolution buffer and PBS and dissolved in 0.1%
formic acid, and the supernatant was recovered. The recovered supernatant sample was
applied to a reverse-phase column (HLB Extraction Cartridge (Oasis)) for antibody removal to
obtain a sample solution. The obtained sample was subjected to reverse-phase liquid
chromatography (Chromatography Nanosystem (KYA Tech Corp.)) to recover a solution
containing only peptides, which was then introduced to a tandem mass spectrometer
quadrupole-TOF mass spectrometer (Waters-MicroMass) for MS/MS analysis to detect the
peptides contained in the sample. As a result, a polypeptide consisting of the amino acid
sequence of SEQ ID NO: 5 was identified as a partial CAPRIN-1 sequence recognized by the
anti-CAPRIN-1 monoclonal antibody #1.
[0150]
(3) Preparation of mouse monoclonal antibodies #2 and #3
In a similar way to that described in the section (1), a fusion protein of the amino acid
sequence of SEQ ID NO: 5 identified in the section (2) and a carrier protein KLH (keyhole
limpet haemocyanin) was mixed as an immunogen with an equal amount of an adjuvant
TiterMax Gold( ) (CytRx Corp.), and this mixture was subcutaneously administered at a dose
of 20 |ug/shot to each mouse at 7-day intervals. After administration with four shots in total,
spleen cells were obtained from the mouse 3 days after the final immunization and fused with
mouse myeloma cells in the same way as in the section (1) to produce hybridomas. Then,

antibodies were screened for, as an indicator, the reactivity of the antibodies contained in the
culture supernatants of the produced hybridomas with a 1 ug/ml solution of CAPRIN-1
proteins prepared in Example 3 of WO2010/016526 or a fusion protein (used as an
immunogen) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein KLH. The 1
p.g/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 and the
fusion protein (30 ug/ml) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein
KLH were each added at 100 ul/well to 96-well plates and left to stand at 4°C for 18 hours.
Each well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.)
solution was added thereto at 400 ul/well and left to stand at room temperature for 3 hours.
The solution in each well was removed, and each well was washed with PBS-T. Then, the
culture supernatant of each hybridoma obtained above was added thereto at 100 ul/well and
left to stand at room temperature for 2 hours. Each well was washed with PBS-T. Then,
HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted
5000-fold with PBS were added thereto at 100 ul/well and left to stand at room temperature
for 1 hour. Each well was washed with PBS-T. Then, a TMB substrate solution
(manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100 ul/well and left to
stand for 5 to 30 minutes to cause color reaction. After the color development, the reaction
was terminated by the addition of IN sulfuric acid at 100 ul/well. The absorbance was
measured at 450 nm and 595 nm using an absorption spectrometer. As a result, hybridomas
producing antibodies having high absorbance were selected.
[0151]
The selected hybridomas were added to a 96-well plate at 0.3 cells/well and cultured in
the plate. One week later, hybridomas forming single colonies in the wells were observed.
The cells in these wells were further cultured, and the cloned hybridomas were screened in the
same way as above for the binding affinity of antibodies produced by the hybridomas to the
amino acid sequence of SEQ ID NO: 5 as a partial CAPRIN-1 sequence as an indicator to
obtain hybridomas producing antibodies against the amino acid of SEQ ID NO: 5.
[0152]

Monoclonal antibodies produced by the obtained hybridomas were screened for
antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1.
Specifically, 106 cells of a human breast cancer cell line MDA-MB-231V were centrifuged in
a 1.5-ml microcentrifuge tube. 100 ul of the culture supernatant of the hybridoma obtained
above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-
labeled goat anti-mouse IgG antibodies (manufactured by Invitrogen Corp.) diluted 500-fold
with PBS containing 0.1% FBS were added thereto and left to stand for 1 hour on ice. After
washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton,
Dickinson and Company). On the other hand, the same operation as above was performed to
prepare a sample using the serum of each untreated 6-week-old Balb/c mouse diluted 500-fold
with a medium for hybridoma culture or prepare a negative control sample by the reaction
only with secondary antibodies, instead of the antibodies. As a result, 2 monoclonal
antibodies (#2 and #3) having stronger fluorescence intensity than that of the negative control,
i.e., reactive with the surface of the breast cancer cells, were obtained.
[0153]
The obtained mouse monoclonal antibodies #2 and #3 were examined for their specific
reaction with the amino acid sequence of SEQ ID NO: 5 as a partial CAPRTN-1 sequence used
as an immunogen. A 30 ug/ml solution of the amino acid sequence of SEQ ID NO: 5
prepared with a 0.1 M aqueous sodium carbonate solution and a partial CAPRTN-1 sequence
free from the amino acid sequence of SEQ ID NO: 5 were each added to a 96-well plate
Immobilizer Amino for ELISA (Nunc) at 100 ug/ml and reacted for one whole day and night
at 4°C to bind the peptides to the wells. A 0.1 M aqueous sodium carbonate solution
containing 10 mM ethanolamine was added to the peptide-bound wells and left to stand at
room temperature for 1 hour. The solution in each well was removed, and each well was
then washed with PBS-T. Then, a Blockace solution was added thereto at 400 ul/well and
left to stand at room temperature for 3 hours. The solution in each well was removed, and
each well was washed with PBS-T. Then, the culture supernatant containing the mouse
monoclonal antibody #2 was added thereto at 50 ul/well and reacted at room temperature for 1

hour. Then, each well was washed with PBS-T, and HRP-labeled anti-mouse IgG (H+L)
antibodies (manufactured by Invitrogen) diluted 5000-fold with a Blockace solution were
added thereto at 50 ul/well and left to stand at room temperature for 1 hour. Each well was
fully washed with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher
Scientific Inc.) was added thereto at 100 ul/well and left to stand for 5 to 30 minutes to cause
color reaction. After the color development, the reaction was terminated by the addition of
IN sulfuric acid at 100 ul/well. The absorbance was measured at 450 run and 595 nm using
an absorption spectrometer. As a result, the mouse monoclonal antibodies #2 and #3 did not
react with the partial CAPRTN-1 sequence free from the amino acid sequence of SEQ ID NO:
5, but specifically reacted only with the amino acid sequence of SEQ ID NO: 5. The results
demonstrated that the polypeptide of SEQ ID NO: 5 contains an epitope region for the anti-
CAPRIN-1 antibodies #2 and #3.
[0154]
Example 3 Preparation of chicken monoclonal antibody against C APRTN-1
Chicken-derived monoclonal antibodies were prepared using as an immunogen a fusion
protein of the amino acid sequence of SEQ ID NO: 5 identified in Example 2(2) and a carrier
protein KLH (keyhole limpet haemocyanin). 300 ug of the immunogen was mixed with an
equal amount of a complete Freund's adjuvant. This mixture was used as an antigen solution
per chicken. The antigen solution was intraperitoneally administered to each 7-week-old
chicken. Then, 7 administrations were performed every 4 weeks to complete immunization.
Four days after the final immunization, the spleen of each chicken was excised and ground
between two sterilized glass slides. Procedures of washing with PBS(-) (manufactured by
Nissui Pharmaceutical Co., Ltd.) and centrifuging at 1500 rpm for 10 minutes to remove the
supernatant were repeated three times to obtain spleen cells. The obtained spleen cells were
mixed with light chain-deficient chicken myeloma cells established from chickens by
transformation using avian reticuloendotheliosis virus, at a ratio of 5:1. A PEG solution
prepared by mixing 200 ul of an IMDM medium containing 10% FBS, which was heated to
37°C, with 800 ul of PEG1500 (manufactured by Boehringer Ingelheim GmbH) was added to

the cell mixture, and then it was left to stand for 5 minutes for cell fusion. After removal of
the supernatant via centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 300
ml of an IMDM medium containing 10% FBS supplemented with 2% equivalent of a HAT
solution (Gibco) (HAT selective medium). This suspension was seeded onto thirty 96-well
plates (Nunc) at 100 ul/well. The spleen cells and the chicken myeloma cells were fused by
culturing for 7 days at 37°C, 5% CO2 to obtain hybridomas. Then, the antibodies were
screened for, as an indicator, the reactivity of the antibody contained in the culture
supernatants of the prepared hybridomas with a solution of CAPRIN-1 proteins prepared as
described in Example 3 of WO2010/016526 or a fusion protein (used as an immunogen) of the
amino acid sequence of SEQ ID NO: 5 and a carrier protein BSA. Specifically, the 1 |u,g/ml
solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 and the fusion
protein (1 (ag/ml) of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA
were each added at 50 ul/well to 96-well plates and left to stand at 4°C for 18 hours. Each
well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.) solution
was added thereto at 300 ul/well and left to stand at room temperature for 3 hours. The
solution in each well was removed, and each well was washed with PBS-T. Then, the culture
supernatant of each hybridoma obtained above was added thereto at 50 ul/well and left to
stand at room temperature for 1 hour. Each well was washed with PBS-T. Then, HRP-
labeled anti-chicken IgY antibodies (manufactured by KPL, Kirkegaard & Perry Laboratories,
Inc.) diluted 1000-fold with PBS were added thereto at 100 ul/well and left to stand at room
temperature for 1 hour. Each well was washed three times with PBS-T. Then, an OPD
substrate solution was added thereto at 50 ul/well and left to stand for 5 to 15 minutes to cause
color reaction. After the color development, the reaction was terminated by the addition of
2N sulfuric acid at 50 ul/well. The absorbance was measured at 490 nm and 630 nm using
an absorption spectrometer. As a result, several hybridomas producing antibodies having
high absorbance were selected.
[0155]

The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in
the plate. One week later, hybridomas forming single colonies in the wells were observed.
The cells in these wells were further cultured, and the cloned hybridomas were screened for, as
an indicator, the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1
proteins or the reactivity of the antibodies against the fusion protein (used as an immunogen)
of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA, to obtain chicken
monoclonal antibodies.
[0156]
Next, these monoclonal antibodies were screened for antibodies reactive with the
surface of breast cancer cells expressing CAPRIN-1. Specifically, 2 x 105 cells of a human
breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube.
50 jLtl of the culture supernatant of each hybridoma obtained above was added thereto and left
to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-chicken IgG
(H+L) antibodies (manufactured by SouthernBiotech) diluted 100-fold with PBS containing
0.5% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS,
the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and
Company). On the other hand, the same operation as above was performed using a medium
for hybridoma culture to prepare a negative control sample. As a result, 4 chicken
monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) having stronger
fluorescence intensity than that of the control, i.e., reactive with the surface of breast cancer
cells expressing CAPRIN-1, were selected. These antibodies can bind to CAPRIN-1
expressed on the surface of breast cancer cells.
[0157]
Example 4 Characterization of selected monoclonal antibody
(1) Characterization of mouse monoclonal antibody
Amplification fragments of genes encoding the variable regions of the mouse
monoclonal antibodies obtained in Example 2 were obtained according to a method described
in Example 5 of WO2010/016526 and analyzed for their gene sequences and amino acid

sequences encoded thereby. The resulting gene sequence encoding the heavy chain variable
region of the mouse-derived monoclonal antibody #1 is shown in SEQ ID NO: 24, and the
amino acid sequence is shown in SEQ ID NO: 19; and the gene sequence encoding the light
chain variable region thereof is shown in SEQ ID NO: 25, and the amino acid sequence is
shown in SEQ ID NO: 23. The resulting gene sequence encoding the heavy chain variable
region of the mouse-derived monoclonal antibody #2 is shown in SEQ ID NO: 14, and the
amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light
chain variable region thereof is shown in SEQ ID NO: 15, and the amino acid sequence is
shown in SEQ ID NO: 13. The resulting gene sequence encoding the heavy chain variable
region of the mouse-derived monoclonal antibody #3 is shown in SEQ ID NO: 14, and the
amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light
chain variable region thereof is shown in SEQ ID NO: 54, and the amino acid sequence is
shown in SEQ ID NO: 53.
[0158]
In other words, the mouse monoclonal antibody #1 was found to comprise the heavy
chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23,
wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino
acid sequences of SEQ ID NOs: 16, 17, and 18, respectively, and the light chain variable
region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs:
20, 21, and 22, respectively. The mouse monoclonal antibody #2 was found to comprise the
heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID
NO: 13, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of
the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light chain
variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ
ID NOs: 10, 11, and 12, respectively. The mouse monoclonal antibody #3 was found to
comprise the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region
of SEQ ID NO: 53, wherein the heavy chain variable region had CDR1, CDR2, and CDR3
consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light

chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of
SEQ ID NOs: 50, 51, and 52, respectively.
[0159]
(2) Characterization of chicken monoclonal antibody
Amplification fragments of genes encoding the variable regions of the chicken
monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) obtained in
Example 3 were obtained according to the method described in Example 4 of
WO2011/096519 and analyzed for their gene sequences and amino acid sequences encoded
thereby. The resulting amino acid sequence of the heavy chain variable region of the chicken
monoclonal antibody #1 is shown in SEQ ID NO: 58, and the amino acid sequence of the light
chain variable region thereof is shown in SEQ ID NO: 62. The amino acid sequence of the
heavy chain variable region of the chicken monoclonal antibody #2 is shown in SEQ ID NO:
63, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID
NO: 65. The amino acid sequence of the heavy chain variable region of the chicken
monoclonal antibody #3 is shown in SEQ ID NO: 69, and the amino acid sequence of the light
chain variable region thereof is shown in SEQ ID NO: 73. The amino acid sequence of the
heavy chain variable region of the chicken monoclonal antibody #4 is shown in SEQ ID NO:
77, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID
NO: 81.
[0160]
In other words, the chicken monoclonal antibody #1 was found to comprise the heavy
chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 62,
wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino
acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain variable
region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs:
59, 60, and 61, respectively. The chicken monoclonal antibody #2 was found to comprise the
heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID
NO: 65, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of

the amino acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain
variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ
ID NOs: 59, 64, and 61, respectively. The chicken monoclonal antibody #3 was found to
comprise the heavy chain variable region of SEQ ID NO: 69 and the light chain variable
region of SEQ ID NO: 73, wherein the heavy chain variable region had CDR1, CDR2, and
CDR3 consisting of the amino acid sequences of SEQ ID NOs: 66, 67, and 68, respectively,
and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid
sequences of SEQ ID NOs: 70, 71, and 72, respectively. The chicken monoclonal antibody
#4 was found to comprise the heavy chain variable region of SEQ ID NO: 77 and the light
chain variable region of SEQ ID NO: 81, wherein the heavy chain variable region had CDR1,
CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 74, 75, and 76,
respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of
the amino acid sequences of SEQ ID NOs: 78, 79, and 80, respectively.
[0161]
Example 5 Preparation of polyclonal antibody against partial CAPRIN-1 polypeptide
present on cancer cell surface
For the purpose of obtaining polyclonal antibodies against partial CAPRIN-1
polypeptides present on cancer cell surface, a polypeptide (CAPRIN-1-derived peptide shown
in SEQ ID NO: 5) comprising the epitope regions for the anti-CAPPJN-1 monoclonal
antibodies #1, #2, and #3, a polypeptide having a region of amino acid residues 50 to 98 in the
human CAPRIN-1 amino acid sequence of SEQ ID NO: 2, and a polypeptide having a region
of amino acid residues 233 to 305 of SEQ ID NO: 2 were synthesized. 1 mg of these
peptides were each mixed as an antigen with an equal volume of an incomplete Freund's
adjuvant (IFA) solution. This mixture was subcutaneously administered to rabbit four times
every two weeks. Then, blood was collected therefrom to obtain antiserum containing
polyclonal antibody against each antigen. The antiserum was further purified using a protein
G carrier (manufactured by GE Healthcare Bio-Sciences Ltd.), followed by replacement with
PBS, to obtain polyclonal antibodies against partial CAPRIN-1 polypeptides present on cancer

cell surface. In addition, the serum of a rabbit that received no antigen was prepared by
purification using a protein G carrier in the same way as above and used as a control antibody.
[0162]
Example 6 Analysis of CAPRIN-1 protein expression on cancer cell
Next, 8 human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-
157, BT-20, MDA-MB-231V, and MRK-nu-1) observed to have a high level of CAPRTN-1
gene expression were examined for their expression of CAPRIN-1 proteins on the cell surface.
5 x 105 cells of the human breast cancer cell lines that were observed above to have the gene
expression were each centrifuged in a 1.5-ml microcentrifuge tube. After adding 2 (a,g (5 (4.1)
of the polyclonal antibodies against CAPRIN-1-derived peptides prepared as described above
in Example 5 thereto, the cells were further mixed with 95 ul of PBS containing 0.1% fetal
bovine serum, and left to stand for 1 hour on ice. After washing with PBS, the resulting
solution was mixed with 2 ul of Alexa 488-labeled goat anti-rabbit IgG antibodies
(manufactured by Invitrogen Corp.) and 98 ul of PBS containing 0.1% fetal bovine serum
(FBS) and left to stand for 30 hours on ice. After washing with PBS, the fluorescence
intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other
hand, the same operation as above was performed using the control antibodies prepared as
described above in Example 5 instead of the polyclonal antibodies against CAPRIN-1-derived
peptides to prepare a control. As a result, the cancer cells treated with the anti-CAPRIN-1
antibodies all exhibited fluorescence intensity at least 35% stronger than that of the control.
This demonstrated that CAPRIN-1 proteins are expressed on the cell membrane surface of the
human cancer cell lines. The rates of enhancement in the fluorescence intensity are
expressed as the rates of increase in mean fluorescence intensity (MFI) in respective cell lines,
which are calculated according to the following formula.
[0163]
Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence
intensity) (%) = ((MFI of cells reacted with the anti-CAPRIN-1 antibodies) - (Control MFI)) /
(Control MFI) x 100

[0164]
Also, the fluorescence intensity was measured in 3 kidney cancer cell lines (Caki-1,
Caki-2, and A498), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3),
a lung cancer cell line (QG56), a prostate cancer cell line (PC3), a uterine cervix cancer cell
line (HeLa), a fibrosarcoma cell line (HT1080), 2 brain tumor cell lines (T98G and U87MG),
a gastric cancer cell line (MNK28), a colorectal cancer cell line (Lovo), and pancreatic cancer
cell lines (Capan-2, MIAPaCa-2, Panc-1, and BxPC-3) using the same approach as above.
As a result, all the cancer cells had fluorescence intensity at least 35% stronger than that of the
control.
[0165]
As with the results obtained above, CAPRIN-1 expression was also confirmed using
the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #1) having the heavy
chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23,
the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #2) having the heavy
chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 13,
and the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #3) having the
heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID
NO: 53, which were obtained in Example 2, and the anti-CAPRIN-1 chicken monoclonal
antibody #1 having the heavy chain variable region of SEQ ID NO: 58 and the light chain
variable region of SEQ ID NO: 62, the anti-CAPRTN-1 chicken monoclonal antibody #2
having the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region
of SEQ ID NO: 65, the anti-CAPRIN-1 chicken monoclonal antibody #3 having the heavy
chain variable region of SEQ ID NO: 69 and the light chain variable region of SEQ ID NO: 73,
and the anti-CAPRIN-1 chicken monoclonal antibody #4 having the heavy chain variable
region of SEQ ID NO: 77 and the light chain variable region of SEQ ID NO: 81 (chicken
monoclonal antibodies #1 to #4), which were obtained in Example 3.
[0166]
Example 7 Immunohistochemical staining

(1) CAPRIN-1 expression in mouse and canine normal tissues
A mouse (Balb/c, female) and a dog (beagle, female) were exsanguinated under ether
anesthesia and under ketamine/isoflurane anesthesia and subjected to abdominal section.
Then, each organ (stomach, liver, eyeball, thymus, muscle, bone marrow, uterus, small
intestine, esophagus, heart, kidney, salivary gland, large intestine, mammary gland, brain, lung,
skin, adrenal gland, ovary, pancreas, spleen, and urinary bladder) was transferred to a 10-cm
dish containing PBS. Each organ was cut open in PBS and perfusion-fixed overnight in a 0.1
M phosphate buffer solution (pH 7.4) containing 4% paraformaldehyde (PFA). The
perfusate was discarded, and the tissue surface of each organ was rinsed with PBS. Each
tissue was placed in a PBS solution containing 10% sucrose in a 50-ml centrifuge tube and
shaken at 4°C for 2 hours using a rotor. The solution was replaced with a PBS solution
containing 20% sucrose, and the resulting solution was left to stand at 4°C until the tissue was
precipitated. Then, the solution was replaced with a PBS solution containing 30% sucrose,
and the resulting solution was left to stand at 4°C until the tissue was precipitated. The tissue
was taken out, and necessary portions were cut off with a surgical knife. Next, OCT
compound (Tissue Tek) was poured onto the tissue surface and spread over the surface.
Then, the tissue was mounted on Cryomold. The Cryomold was placed on dry ice to quickly
freeze the tissue, and then the tissue was sliced into 10 to 20 jam thick using Cryostat
(manufactured by Leica Biosystems), and dried in air, together with the glass slide, for 30
minutes using a hair dryer to prepare a glass slide with a tissue slice placed thereon. Next,
the glass slide was placed in a staining bottle filled with PBS-T (physiological saline
containing 0.05% Tween 20), and procedures of replacing PBS-T with a fresh one every 5
minutes were performed three times. Redundant water around each section was wiped off
with Kimwipe. The section on the glass slide was encircled with a Dako pen (manufactured
by Dako Japan Inc.). Then, MOM mouse Ig blocking reagent (Vectastain) for the mouse
tissues and a PBS-T solution containing 10% FBS for the canine tissues were applied thereto
as blocking solutions, and the glass slide was left to stand at room temperature for 1 hour in a
moist chamber.

[0167]
Next, a cancer cell surface-reactive polyclonal antibody against the CAPRIN-1-derived
peptide (SEQ ID NO: 5) prepared in Example 5 was prepared into a 10 ug/ml solution with a
blocking solution, and this solution was applied thereto. The glass slide was left to stand
overnight at 4°C in a moist chamber. After washing with PBS-T for 10 minutes three times,
MOM biotin-labeled anti-IgG antibodies (Vectastain) diluted 250-fold with a blocking
solution were applied thereto, and the glass slide was left to stand at room temperature for 1
hour in a moist chamber. After washing with PBS-T for 10 minutes three times, Avidin-
Biotin ABC reagent (Vectastain) was applied thereto, and the glass slide was left to stand at
room temperature for 5 minutes in a moist chamber. After washing with PBS-T for 10
minutes three times, a DAB staining solution (10 mg of DAB + 10 ul of 30% H2O2/ 50 ml of
0.05 M tris-HCl (pH 7.6)) was applied thereto, and the glass slide was left to stand at room
temperature for 30 minutes in a moist chamber. After rinsing with distilled water, a
hematoxylin reagent (manufactured by Dako Japan Inc.) was applied thereto, and the glass
slide was left to stand at room temperature for 1 minute and then rinsed with distilled water.
The glass slide was placed in 70%, 80%, 90%, 95%, and 100% ethanol solutions in this order
for 1 minute per solution and then left to stand overnight in xylene. The glass slide was taken
out and mounted in Glycergel Mounting Medium (manufactured by Dako Japan Inc.),
followed by observation. As a result, the intracellular expression of CAPRIN-1 was slightly
observed in respective tissues of the salivary gland, kidney, colon, and stomach. Its
expression, however, was not observed on the cell surface of these tissues. In addition, no
expression was observed in tissues derived from the other organs.
[0168]
(2) Expression of CAPRIN-1 in canine breast cancer tissue
Frozen breast cancer tissues of dogs pathologically diagnosed as malignant breast
cancer were used in the preparation of frozen section slides and immunohistochemical staining
using the polyclonal antibodies against the CAPRIN-1-derived peptide (SEQ ID NO: 5)

prepared in Example 5, in the same way as above. As a result, the expression of CAPRTN-1
was observed in the canine breast cancer tissues.
[0169]
(3) Expression of CAPRIN-1 in various human cancer tissues
Paraffin-embedded human various cancer tissue array samples (manufactured by US
Biomax, Inc.) were used in immunohistochemical staining using the polyclonal antibodies
(prepared in Example 5) against the CAPRTN-1-derived peptide (SEQ ID NO: 5) in the same
way as above. As a result, the expression of CAPRTN-1 was observed in esophageal cancer,
colon cancer, rectal cancer, lung cancer, pancreatic cancer, kidney cancer, urinary bladder
cancer, and uterine cervix cancer.
[0170]
Example 8 Preparation of human-mouse chimeric monoclonal antibody
The gene amplification fragment prepared in Example 4 comprising the sequence
(SEQ ID NO: 14) of the heavy chain variable region of the mouse monoclonal antibody #2
was treated at both ends with a restriction enzyme, then purified, and inserted according to a
conventional method into a vector pcDNA4/myc-His (manufactured by Invitrogen Corp.)
already having gene inserts of a mouse antibody-derived leader sequence and a human IgGi H
chain constant region comprising the amino acid sequence of SEQ ID NO: 48. Also, the
gene amplification fragment comprising the sequence (SEQ ID NO: 15) of the light chain
variable region of the mouse monoclonal antibody #2 was treated at both ends with a
restriction enzyme, then purified, and inserted according to a conventional method into a
vector pcDNA3.1/myc-His (manufactured by Invitrogen Corp.) already having gene inserts of
a mouse antibody-derived leader sequence and a human IgGi L chain constant region
comprising the amino acid sequence of SEQ ID NO: 49.
[0171]
Next, the recombinant vector having the insert of the nucleotide sequence encoding the
heavy chain variable region (SEQ ID NO: 14) of the mouse monoclonal antibody #2 and the
recombinant vector having the insert of the nucleotide sequence encoding the light chain

variable region (SEQ ID NO: 15) of the mouse monoclonal antibody #2 were introduced into
CHO-K1 cells (obtained from Riken Cell Bank). Specifically, 2 x 105 CHO-K1 cells were
cultured in a Ham's F12 medium (manufactured by Invitrogen Corp.) containing 1 ml of 10%
FBS per well in a 12-well culture plate, and washed with PBS(-). Then, a fresh Ham's F12
medium containing 1 ml of 10% FBS per well was added thereto. 250 ng each of the vectors
in 30 ul of OptiMEM (manufactured by Invitrogen Corp.) was mixed with 30 ul of Polyfect
transfection reagent (manufactured by Qiagen N.V.), and this mixture was added to each well.
The CHO-K1 cells cotransfected with the recombinant vectors were cultured in a Ham's F12
medium containing 10% FBS supplemented with 200 ug/ml Zeocin (manufactured by
Invitrogen Corp.) and 200 (j.g/ml Geneticin (manufactured by Roche Diagnostics K.K.) and
then seeded in a 96-well plate at 0.5 cells/well to prepare a cell line stably producing a human-
mouse chimeric monoclonal antibody #1 (#1) having the variable regions of the mouse
monoclonal antibody #1. Cell lines stably producing a human-mouse chimeric monoclonal
antibody #2 (#2) or a human-mouse chimeric monoclonal antibody #3 (#3) were also prepared
in the same way as above as to the mouse monoclonal antibodies #2 and #3.
[0172]
Each prepared cell line was cultured for 5 days in a 150-cm flask at 5 x 105 cells/ml in
30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture
supernatants containing #1, #2, or #3.
[0173]
Also, cell lines stably producing human-mouse chimeric comparative antibodies 1 to 11
were prepared in the same way as above respectively, on the basis of the following anti-
CAPRTN-1 mouse-derived monoclonal antibodies disclosed in WO2010/016526 as
comparative antibodies: a comparative antibody 1 having the heavy chain variable region of
SEQ ID NO: 26 and the light chain variable region of SEQ ID NO: 27; a comparative antibody
2 having the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region
of SEQ ID NO: 29; a comparative antibody 3 having the heavy chain variable region of SEQ
ID NO: 30 and the light chain variable region of SEQ ID NO: 31; a comparative antibody 4

having the heavy chain variable region of SEQ ID NO: 32 and the light chain variable region
of SEQ ID NO: 33; a comparative antibody 5 having the heavy chain variable region of SEQ
ID NO: 34 and the light chain variable region of SEQ ID NO: 35; a comparative antibody 6
having the heavy chain variable region of SEQ ID NO: 36 and the light chain variable region
of SEQ ID NO: 37; a comparative antibody 7 having the heavy chain variable region of SEQ
ID NO: 38 and the light chain variable region of SEQ ID NO: 39; a comparative antibody 8
having the heavy chain variable region of SEQ ID NO: 40 and the light chain variable region
of SEQ ID NO: 41; a comparative antibody 9 having the heavy chain variable region of SEQ
ID NO: 42 and the light chain variable region of SEQ ID NO: 43; a comparative antibody 10
having the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region
of SEQ ID NO: 45; and a comparative antibody 11 having the heavy chain variable region of
SEQ ID NO: 46 and the light chain variable region of SEQ ID NO: 47. Each prepared cell
line was cultured for 5 days in a 150-cm2 flask at 5 x 105 cells/ml in 30 ml of a serum-free
OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture supernatants
containing respective human-mouse chimeric comparative monoclonal antibodies 1 to 11.
[0174]
Example 9 Preparation of human-chicken chimeric monoclonal antibody
On the basis of the chicken monoclonal antibody #1 obtained in Example 3, a cell line
stably producing a human-chicken chimeric antibody #1 having the variable regions of the
chicken monoclonal antibody #1 was prepared according to the method described in Example
4(2) of WO2011/096519on the basis of. The prepared cell line was cultured for 5 days in a
150-cm flask at 5 x 10 cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured
by Invitrogen Corp.) to obtain a culture supernatant containing human-chicken chimeric
antibody #1.
[0175]
Also, on the basis of the chicken monoclonal antibodies #2, #3, and #4, cell lines stably
producing a human-chicken chimeric antibody #2, #3, or #4 were also prepared using the same

approach as above. Each prepared cell line was used to obtain culture supernatants
containing the human-chicken chimeric antibody #1, #2, #3, or #4.
[0176]
Example 10 Expression analysis of CAPRIN-1 on surface of various cancer cells
using mouse monoclonal antibodies #1, #2, and #3 and chicken monoclonal antibodies #1, #2,
#3,and #4
Next, the human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-
157, BT-20, MDA-MB-231V, and MRK-nu-1), the kidney cancer cell lines (Caki-1, Caki-2,
A498, and ACHN), the urinary bladder cancer cell line (T24), the ovary cancer cell line
(SKOV3), the lung cancer cell lines (QG56 and A549), the pancreatic cancer cell lines
(Capan-2 and MIAPaCa-2), the prostate cancer cell line (PC3), the uterine cervix cancer cell
line (SW756), the fibrosarcoma cell line (HT1080), the brain tumor cell lines (T98G, U87MG,
U251, SNB19, and U373), the gastric cancer cell lines (MNK28 and MNK45), the colorectal
cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), the leukemia cell line (AML5),
and the lymphoma cell line (Ramos) observed to have CAPRIN-1 gene expression were
examined for their expression of CAPRIN-1 proteins on the cell surface using the culture
supernatants respectively containing #1, #2, and #3 obtained in Example 2 and the chicken
monoclonal antibodies #1, #2, #3, and #4 obtained in Example 3. 106 cells of each cell line
were centrifuged in each 1.5-ml microcentrifuge tube. Each culture supernatant (100 ul)
containing any of the antibodies #1, #2, and #3 and the chicken monoclonal antibodies #1, #2,
#3, and #4 was added to the tube and left to stand for 1 hour on ice. After washing with PBS,
FITC-labeled goat anti-mouse IgG (H+L) antibodies (manufactured by Jackson
ImmunoResearch Laboratories, Inc.) diluted with PBS containing 0.1% FBS for the mouse-
derived antibodies or FITC-labeled goat anti-chicken IgG (H+L) antibodies (manufactured by
SouthernBiotech) diluted 100-fold with PBS containing 0.1% FBS for the chicken-derived
antibodies were added thereto and left to stand at 4°C for 30 minutes. After washing with
PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and
Company). The negative control used was cells reacted only with secondary antibodies. As

a result, all the cells each treated with any of the antibodies #1, #2, and #3 and the chicken
monoclonal antibodies #1 to #4 had fluorescence intensity at least 35% stronger than that of
the negative control. This demonstrated that CAPRJN-1 proteins are expressed on the cell
membrane surface of the human cancer cell lines. The rates of enhancement in the
fluorescence intensity was expressed as the rates of increase in mean fluorescence intensity
(MFI) in respective cell lines, which are calculated according to the following formula.
[0177]
Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence
intensity) (%) = ((MFI of cells reacted with the anti-CAPRIN-1 antibodies) - (Control MFI)) /
(Control MFI) x 100
[0178]
Example 11 Antitumor activity against cancer cells of antibody against CAPRIN-1 -
derived peptide (SEQ ID NO: 5)
In order to evaluate the antibodies against the CAPRIN-1-derived peptide (SEQ ID
NO: 5) for the strength of its cytotoxicity against cancer cells expressing CAPRIN-1, ADCC
activity was determined. The polyclonal antibodies (prepared in Example 5) against the
peptide shown in SEQ ID NO: 5 were used in this evaluation. Similar evaluation was
conducted using polyclonal antibodies against other human CAPRIN-1-derived peptides
(polyclonal antibodies against amino acid residues 50 to 98 in the amino acid sequence of
human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to 305 in the
amino acid sequence of human CAPRIN-1, which were prepared in Example 5) as antibodies
for comparison or the rabbit serum-derived control antibodies prepared in Example 5 as a
negative control.
[0179]
10 cells of the human breast cancer cell line MCF7, the human colorectal cancer cell
line HCT-116, the human pancreatic cancer cell line MIAPaCa-2, the human kidney cancer
cell line Caki-2, and the human lung cancer cell line QG56 observed to have CAPRIN-1
expression were each collected into a 50-ml centrifuge tube, and 100 uCi of chromium 51 was

then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed
three times with an RPMI1640 medium containing 10% fetal calf serum and added at 2 x 103
cells/well to a 96-well V-bottom plate. The polyclonal antibodies against the human
CAPRJN-1-derived peptide (SEQ ID NO: 5) and two types of polyclonal antibodies against
other human CAPRTN-1 -derived peptides (polyclonal antibodies against amino acid residues
50 to 98 of human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to
305 of human CAPRJN-1) were each added thereto at 1 (xg/well. Lymphocytes separated
from human peripheral blood according to a conventional method were further added thereto
at 4 x 105 cells/well and cultured for 4 hours at 37°C, 5% CO2. After the culture, the amount
of chromium (Cr) 51 released from damaged cancer cells was measured in the culture
supernatant to calculate the ADCC activity against the cancer cells due to the polyclonal
antibodies against the human CAPRIN-1-derived peptides. As a result, all the polyclonal
antibodies obtained by immunization with the human partial CAPRJN-1 peptides having the
amino acid sequence of amino acid residues 50 to 98 or amino acid residues 233-305 of
human CAPRJN-1 had activity less than 10% against the human breast cancer cell line MCF7,
the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line
MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line
QG56. By contrast, the groups of the cells treated with the polyclonal antibodies against the
human CAPRJN-1-derived peptide (SEQ ID NO: 5) exhibited 25% or higher cytotoxic activity
against all the cancer cell lines. The negative control antibodies had activity less than 4%
against all the cancer cells. These results revealed that antibodies against CAPRJN-1 shown
in SEQ ID NO: 5 exerts strong cytotoxic activity against cancer cells expressing CAPRJN-1.
[0180]
These results were obtained via determination of cytotoxic activity by, as described
above, mixing the anti-CAPRJN-1 antibody used in the present invention, lymphocytes, and 2
x 10 cells of each cancer cell line with incorporated chromium 51;culturing the cells for 4
hours; after the culture, measuring the amount of chromium 51 released into the medium; and

calculating the cytotoxic activity against each cancer cell line according to the following
formula*.
[0181]
Expression: Cytotoxic activity (%) = [Amount of chromium 51 released from the
target cells treated with the antibody against CAPRIN-1 and lymphocytes] / [Amount of
chromium 51 released from target cells treated with IN hydrochloric acid] x 100
[0182]
The human-mouse chimeric monoclonal antibodies #1, #2, and #3 obtained in Example
8 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 obtained in
Example 9 were evaluated for their cytotoxic activity against human cancer cells. The
culture supernatant of each cell line producing any of #1, #2, and #3 and the human-chicken
chimeric monoclonal antibodies #1, #2, #3, and #4 was purified using Hitrap Protein A
Sepharose FF (manufactured by GE Healthcare Bio-Sciences Ltd.). After replacement with
PBS(-), the solution was filtered through a 0.22-um filter (manufactured by Millipore Corp.).
The resulting antibody was used for activity assay. 106 cells each of the human breast cancer
cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer
cell line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer
cell line QG56 were collected into a 50-ml centrifuge tube, and 100 uCi of chromium 51 was
then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed
three times with an RPMI1640 medium containing 10% FBS and added at 2 x 103 cells/well to
a 96-well V-bottom plate to prepare target cells. The purified antibodies (human-mouse
chimeric monoclonal antibodies #1, #2, and #3 and human-chicken chimeric monoclonal
antibodies #1, #2, #3, and #4) and the human-mouse chimeric comparative monoclonal
antibodies 1 to 11 obtained in Example 8 were each added thereto at 1.3 ug/well. A cell
population containing human NK cells was separated using a conventional method from
human peripheral blood lymphocytes prepared according to a conventional method. The cell
population containing human NK cells that was used in this evaluation was prepared as
follows: human peripheral blood mononuclear cells separated using a specific gravity

separation solution Histopaque for peripheral blood mononuclear cell separation (Sigma-
Aldrich Corp.) were reacted with FITC fluorescent dye-labeled antibodies (anti-human CD3
antibody, anti-human CD20 antibody, anti-human CD 19 antibody, anti-human CDllc
antibody, or anti-HLA-DR antibody (Becton, and Dickinson and Company)); and a cell
population containing NK cells unstained with the antibodies was separated therefrom using a
cell sorter (FACS Vantage SE (Becton, and Dickinson and Company)), or a cell population
was separated with human NK cell separation kit (manufactured by Miltenyi Biotec K.K.).
The separated cell population containing NK cells was added to the plate at 2 x 105 cells/well
and cultured for 4 hours at 37°C, 5% CO2. After the culture, the amount of chromium 51
released from damaged tumor cells was measured in the culture supernatant to calculate the
cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. The negative
control used was cells treated with isotype control antibodies. As a result, the isotype control
antibodies used and the human-mouse chimeric comparative monoclonal antibodies 1 to 11
had cytotoxic activity of less than 5% against MCF7, less than 3% against HCT-116, 7%
against MIAPaCa-2, less than 8% against Caki-2, and less than 5% against QG56. By
contrast, the human-mouse chimeric monoclonal antibody #1 and the human-chicken chimeric
monoclonal antibodies #1 to #4 had cytotoxic activity of 30% or higher against MCF7, 19% or
higher against HCT-116, 28% or higher against MIAPaCa-2, 34% or higher against Caki-2,
and 10% or higher against QG56. Also, the human-mouse chimeric monoclonal antibodies
#2 and #3 had cytotoxic activity of 32% or higher against MCF7, 18% or higher against HCT-
116, 32% or higher against MIAPaCa-2, 18% or higher against Caki-2, and 10% or higher
against QG56. Likewise, the isotype control antibodies used and the comparative antibodies
1 to 11 used had cytotoxic activity less than 4% against all other cancer cells: breast cancer
cell lines ZR75-1, T47D, Hs578T, BT-20, SK-BR-3, MDA-MB-231V, and MRK-nu-1,
glioma cell lines T98G and U373, a lung cancer cell line A549, kidney cancer cell lines Caki-1
and ACHN, a uterine cervix cancer cell line SW756, a urinary bladder cancer cell line T24,
gastric cancer cell lines MKN28 and MKN45, a colorectal cancer cell line SW480, a leukemia
cell line AML5, and a lymphoma cell line Ramos. By contrast, the human-mouse chimeric

monoclonal antibodies #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies
#1, #2, #3, and #4 were observed to have 10% or higher cytotoxic activity against these cell
lines. These results showed that the obtained monoclonal antibodies #1, #2, and #3 and
human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 against CAPRIN-1 damage
CAPRIN-1-expressing cancer cells through their ADCC activity, and it was demonstrated that
the human-mouse chimeric monoclonal antibodies #1, #2, and #3 and the human-chicken
chimeric monoclonal antibodies #1, #2, #3, and #4 exhibit stronger cytotoxic activity against
human cancer cells than that of the comparative antibodies 1 to 11.
[0183]
Also, the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 were
evaluated in the same way as above for their cytotoxic activity against the human breast cancer
cell line MDA-MB-436, the human kidney cancer cell line Caki-1, the human lung cancer cell
line A549, the human pancreatic cancer cell line Panc-1, and the human colorectal cancer cells
DLD-1 observed to have CAPRIN-1 gene expression. Further, human-chicken chimeric
antibodies #1 and #2 against CAPRIN-1 described in Example 4 of WO2011/096517 were
used as comparative antibodies 12 and 13, respectively; a human-chicken chimeric antibody
#1 against CAPRIN-1 described in Example 4 of WO2011/096519 was used as a comparative
antibody 13; a human-chicken chimeric antibody #1 and mouse monoclonal antibodies #2, #3,
#4, #5, and #6 against CAPRIN-1 described in Example 4 of WO2011/096528 were used as
comparative antibodies 14, 15, 16, 17, 18, and 19 respectively; mouse monoclonal antibodies
#1, #2, and #3 against CAPRIN-1 described in Example 3 of WO2011/096533 were used as
comparative antibodies 20, 21, and 22, respectively; and mouse monoclonal antibodies #1, #2,
and #3 against CAPRIN-1 described in Example 3 of WO2011/096534 were used as
comparative antibodies 23, 24, and 25, respectively, for evaluation of the cytotoxic activity.
Specifically, 106 cells of the human colorectal cancer cell line DLD-1 were collected into a 50-
ml centrifuge tube, and 100 uCi of chromium 51 was then added thereto, followed by
incubation at 37°C for 1 hour. Then, the cells were washed three times with an RPMI1640
medium containing 10% FBS and added at 2 x 103 cells/well to a 96-well V-bottom plate to

prepare target cells. Next, the human-chicken chimeric monoclonal antibodies #1 to #4 and
the comparative antibodies 12 to 25 were each added thereto at 1 ug/well. A cell population
containing human NK cells prepared according to a conventional method was further added
thereto at 105 cells/well and cultured for 4 hours at 37°C, 5% C02. After the culture, the
amount of chromium 51 released from damaged tumor cells was measured in the culture
supernatant to calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the
cancer cells. Cytotoxicity against MDA-MB-436, Caki-1, A549, and Panc-1 was also
evaluated in the same way as above. As a result, all the comparative antibodies 12 to 25 had
5% or lower cytotoxic activity against MDA-MB-436, whereas the human-chicken chimeric
monoclonal antibodies #1, #2, #3, and #4 exhibited 18% or higher cytotoxic activity against
this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity
against Caki-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4
exhibited 14% or higher cytotoxic activity against this cell line. All the comparative
antibodies 12 to 25 had 5% or lower cytotoxic activity against A549, whereas the human-
chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 12% or higher cytotoxic
activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower
cytotoxic activity against Panc-1, whereas the human-chicken chimeric monoclonal antibodies
#1, #2, #3 and #4 exhibited 18% or higher cytotoxic activity against this cell line. All the
comparative antibodies 12 to 25 had 7% or lower cytotoxic activity against DLD-1, whereas
the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 15% or
higher cytotoxic activity against this cell line.
[0184]
These results were obtained via determination of cytotoxic activity by, as described
above, mixing the anti-CAPRJN-1 antibody used in the present invention, lymphocytes (cell
population containing NK cells), and 2 x 103 cells of each cancer cell line with incorporated
chromium 51; culturing the cells for 4 hours; after the culture, measuring the amount of
chromium 51 released into the medium; and calculating the cytotoxic activity against each
cancer cell line according to the following formula*.

[0185]
Expression: Cytotoxic activity (%) = [Amount of chromium 51 released from the
target cells treated with the antibody against CAPRIN-1 and lymphocytes (cell population
containing NK cells)] / [Amount of chromium 51 released from target cells treated with IN
hydrochloric acid] x 100
[0186]
Example 12 The number of CAPRIN-1 molecules on surface of various cancer cells
recognized by anti-CAPRIN-1 monoclonal antibodies #1, #2, and #3
Human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-
20, MDA-MB-231V, and MRK-nu-1), kidney cancer cell lines (Caki-1, Caki-2, A498, and
ACHN), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), lung
cancer cell lines (QG56 and A549), pancreatic cancer cell lines (MIAPaCa-2 and Capan-2), a
prostate cancer cell line (PC3), a uterine cervix cancer cell line (SW756), a fibrosarcoma cell
line (HT1080), brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), gastric
cancer cell lines (MNK28 and MNK45), colorectal cancer cell lines (HT29, Lovo, CaCo2,
SW480, and HCT116), a leukemia cell line (AML5), and a lymphoma cell line (Ramos) were
examined using an assay kit for the number of molecules "QIFIKIT" (manufactured by Dako
Japan Inc.) for the number of CAPRIN-1 molecules on their cell surface recognized by the
mouse monoclonal antibodies #1, #2, and #3 obtained in Example 2. Similarly, the number
of CAPRIN-1 molecules on the surface of these various cancer cells was also examined using
the comparative monoclonal antibodies 1 to 11.
[0187]
Specifically, according to the protocol attached to the kit, each antibody (mouse
monoclonal antibodies #1, #2, and #3 and comparative antibodies 1 to 11) was diluted into 5
Hg/ml at final concentration with PBS, and this dilution was added to each cell line and reacted
for 30 minutes. After washing with PBS, fluorescently labeled anti-mouse IgG antibodies
attached to the kit were added as secondary antibodies, together with calibration beads
attached to the kit, to each cell line and left to stand for 45 minutes on ice. Each cell line and

the calibration beads were washed with PBS. Then, the fluorescence intensity was measured
using FACSCalibur (Becton, Dickinson and Company) to obtain a mean fluorescence intensity
value (mean) for all the antibodies described above. The negative control used was cells
reacted with isotype control antibodies, and a mean was also obtained. Each mean
fluorescence intensity value (mean) was used to calculate the number of molecules according
to the protocol attached to the kit. As a result, the number of CAPRIN-1 molecules on the
surface of various cancer cells recognized by the mouse monoclonal antibodies #1, #2, and #3
was 105 or more per cell for all the examined human cancer cell lines. On the other hand, the
number of molecules recognized by the comparative antibodies 1 to 11 was less than 105 per
cell.
Industrial Applicability
[0188]
The antibody of the present invention is useful in the treatment and/or prevention of
cancer.
[0189]
All publications, patents, and patent applications cited herein are incorporated herein by
reference in their entirety.

We Claims
1. An antibody or a fragment thereof which has immunological reactivity with a partial
CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an
amino acid sequence having 80% or higher sequence identity to the amino acid sequence.
2. The antibody or the fragment thereof according to claim 1, wherein the antibody or
the fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1
protein.
3. The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody
is a monoclonal antibody or a polyclonal antibody.
4. The antibody or the fragment thereof according to any one of claims 1 to 3, wherein
the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain
antibody, or a multispecific antibody.
5. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 10, 11, and 12 and has immunological reactivity with the
CAPRIN-1 protein.
6. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 20, 21, and 22 and has immunological reactivity with the
CAPRIN-1 protein.

7. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 50, 51, and 52 and has immunological reactivity with the
CAPRIN-1 protein.
8. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 59, 60, and 61 and has immunological reactivity with the
CAPRIN-1 protein.
9. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 59, 64, and 61 and has immunological reactivity with the
CAPRIN-1 protein.

10. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity
determining regions of SEQ ID NOs: 70, 71, and 72 and has immunological reactivity with the
CAPRIN-1 protein.
11. The antibody or the fragment thereof according to any one of claims 1 to 4, which
comprises a heavy chain variable region comprising complementarity determining regions of
SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity

determining regions of SEQ ID NOs: 78, 79, and 80 and has immunological reactivity with the
CAPRIN-1 protein.
12. The antibody or the fragment thereof according to any one of claims 1 to 11, wherein
the antibody or the fragment thereof is conjugated with an antitumor agent.
13. A pharmaceutical composition for treatment and/or prevention of cancer, comprising
the antibody or the fragment thereof according to any one of claims 1 to 12 as an active
ingredient.
14. The pharmaceutical composition according to claim 13, wherein the cancer is breast
cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric
cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
15. A pharmaceutical combination for treatment and/or prevention of cancer, comprising a
pharmaceutical composition according to claim 13 or 14 and a pharmaceutical composition
comprising an antitumor agent.
16. A DNA encoding the antibody or the fragment thereof according to any one of claims 1
to 11.
17. A method for treating and/or preventing cancer, comprising administering the antibody
or the fragment thereof according to any one of claims 1 to 12, the pharmaceutical
composition according to claim 13 or 14, or the pharmaceutical combination according to
claim 11, to a subject.